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Summary 
It has been known for many years that vitamin A protects man and animals from 
infectious diseases. Thus, vitamin A deficiency which is a problem in large parts of the 
world, leads to higher risk of infection-related deaths of children in theses areas. 
Supplementation of vitamin A has on the other hand been shown to protect against both 
infections and infection-related deaths, and this has been linked to overall stimulation of 
the immune system.  However, despite numerous studies in man and animal models, it is 
still not clear how vitamin A stimulates the immune system.  In our lab we have for 
several years studied the role of vitamin A on purified populations of B-and T-
lymphocytes in vitro. We have found that proliferation of both human and murine B-cell 
precursors is inhibited by physiological levels of the vitamin A metabolite retinoic acid 
(RA) (Blomhoff et al., 1992; Fahlman et al., 1995; Naderi and Blomhoff, 1999). Also 
naive human B-cells are inhibited by RA (Fahlman et al., 1995), whereas the apoptosis in 
these cells is prevented (Lomo et al., 1998). In contrast to the effects on B-cells, we have 
shown that the proliferation of normal human T-lymphocytes is stimulated by RA 
(Ertesvag et al., 2002) and that also in T-cells, the apoptosis is prevented (Engedal et al., 
2004). Furthermore, we have recently demonstrated that the effects of RA on both 
proliferation and apoptosis in T-cells, at least in part, are mediated via induced production 
of IL-2 (Engedal et al., 2004).  
 
In this thesis we wished to elucidate if RA, independent of its ability to induce IL-2, also 
is able to enhance IL-2 mediated signaling in T-cells. First we documented that RA 
indeed was able to enhance IL-2 mediated proliferation.  Thus, in the absence of serum, 
RA enhanced the proliferation of purified T-cells stimulated with anti-CD3 and saturating 
concentrations of IL-2, by a factor of 2-3. We next wished to determine how RA affected 
the cell cycle machinery that regulates G1-S-transition, and we found that RA first of all 
targeted cyclin D3. Thus, by enhancing the level of cyclin D3 at the mRNA and protein 
level, this resulted in increased phosphorylation of pRB, which is known to be the critical 
event in driving the cells into S-phase. Furthermore, we demonstrated that the effect of 
RA to enhance the expression of cyclin D3 leading to pRB phosphorylation and 
proliferation, was dependent on JAK. JAK-activation occurs downstream of the IL-2 
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receptor, and we found that the JAK-inhibitor AG-490 inhibited the effect of RA.  
Finally, we were able to show that the effect of RA on OKT3/IL-2 induced T-cell 









































ACAD Activated T cell autonomous death 
AICD Activation-induced cell death 
APC Antigen presenting cell 
APC Anaphase-promoting complex 
APS Ammonium persulphate 
Bis N, N-methylene bisacrylamide 
BH-domains Bcl-2 homology domains 
bp Base pair 
BrdU Bromodeoxyuridine 
BSA Bovine serum albumine 
CD Cluster of differentiation 
CDK Cyclin-dependent kinase 
CFSE Carboxy-fluorescein diacetate, succinimedyl ester 
CKI CDK inhibitor 
ConA Concanavalin A 
Cpm Counts per minute 
Cyt c Cytocrom c 
DEPC Diethyl pyrocarbonate 
DMSO Dimethyl sulphoxide 
DNA Deoxyribonucleic acid 
DRB 5, 6-dichloro 1β-D-ribofuranosylbenzimidazole 
EDTA Ethylene diamine tetra acetic acid 
ERK Ectracellular regulated kinase 
EtBr Ethidium bromide 
FACS Fluorescence activated cell sorter 
FBS Fetal bovine serum 
FITC Fluorescein 
G1 Gap 1 (in the cell cycle) 
G2 Gap 2 (in the cell cycle) 
GITC Guanidine isothiocyanate 
GSK Glycogen synthase kinase 
HCl Hydrochloric acid 
HEPES N-[2-Hydroxyethyl] piperazine-N’-[2-ethanesulphonic acid] 
HLA Human Leukocyte antigen 
HRP Horse raddish peroxidase 




IL-2R IL-2 receptor 
ITAM Immunoreceptor tyrosin-based activation motif 
JAK Janus kinase 
JNK c-Jun N-terminal kinase 
LAT Linker for Activation of T cells 
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MAPK Mitogen-activated kinase 
MAPKK MAPK kinase 
MAPKKK MAPK kinase kinase 
mCi mCievert 
MHC Major histocompatibility complex 
MNC Mononuclear cells 
M-phase Mitosis 
NR Nuclear receptors 
PBL Peripheral blood lymphocytes 
PBMC Peripheral blood mononuclear cells 
PBS Phosphate buffered saline solution 
PDK1 Phosphoinositode-dependent protein kinase 
PHA Phytohemagglutinin 
PH-domain Pleckstrin homology domain 
PI Phosphoinositide 
PI Propidium iodide 
PI3K Phospho-inositol 3 kinase 
PIP3 Phosphateidylinositol (3, 4, 5) Triphosphate 
PKB Protein kinase B 
PKC Protein kinase C 
PMSF Phenyl-methyl-sulphonyl fluorid 
ppRB Hyperphosphorylated RB 
pRB The retinoblastoma protein 
PS Penicillin and Streptomycin 
PtdIns Phosphateidylinositol 
PTB Phosphotyrosine-binding 
PTK  Protein tyrosine kinase 
RA Retionic acid 
RAR Retionic Acid Receptor 
RARE Retionid acid response element 
RNase Ribonucleases 
RNA Ribonucleic acid 
R-point Restriction point 
RXR Retionid X Receptor 
S Synthesis 
SDS-PAGE SDS-polyacrylalaide gel electrophoresis 
SEM Standars error of the mean 
SH2 Src homology 2 
SH3 Src homology 3 
STAT Signal transducers and activators of transcription 
tBid Truncated Bid 
TCR T cell receptor 
TNFα Tumor necrosis factor 
TPA 12-O-tetradecaanoylphorbol 13-acetate 
TEMED N, N, N’, N’-tetramethylenediamine 
UV Ultraviolet 
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V Volt 
VAD Vitamin A deficient 
YXXM-motif Tyr-X-X-Met-motif 
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1.1 The cell cycle 
The cell cycle is a highly ordered process which is defined as the period between two cell 
divisions (figure 1). In eukaryotic cells the cell cycle is divided into phases termed G1, S, 
G2 and M. G1 and G2 are Gap phases. G1 is the interval between mitosis (M phase) and 
DNA synthesis (S phase). During the G1 phase the cell integrates mitogenic and growth 
inhibitory signals, and makes the decision to proceed, pause or exit the cell cycle. S is the 
phase of DNA synthesis where the entire genome is replicated. After transition through 
the S phase, the cell enters the G2 phase where it prepares for the division process. The 
G2 phase is another point in the cell cycle, at which the cycle can be arrested, if for 
instance the DNA replication has not been completed or if DNA repair has to be 
performed because of DNA damage. During the M phase the replicated chromosomes are 
segregated into separate nuclei, and the cell divides into two daughter cells. G0 is a 
specialized resting state for cells that have excited the cell cycle, where they stay either 
temporarily or permanently (Alberts et al., 2002). 
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Figure 1. The four phases of the cell cycle (see text for details). During interphase the cell 
grows constantly, and during M phase the cell divides (Alberts et al., 1994).  
 
1.1.1 The cell cycle machinery 
i) General description 
The cell cycle is controlled by different kinase complexes; each consists of a catalytic 
subunit, the cyclin dependent kinase (CDK), and a regulatory subunit, the cyclin. It is 
first when the CDKs bind to their specific cyclins that they become active, provided that 
these subunits are available (Pines, 1999). Although the levels of CDKs remain relatively 
constant throughout the cell cycle, cyclin abundance oscillates as a result of programmed 
synthesis and degradation through proteolysis (figure 2) (Coqueret, 2002; Ekholm and 
Reed, 2000). This ensures that the DNA is accurately replicated once per cell cycle, and 
that the chromosomes are segregated equally to daughter cells at the right time. The level 
of two classes of cyclins increases during the G1 phase of the cell cycle, D-type cyclins 
(cyclins D1, D2 and D3) and E-type cyclins (cyclins E1 and E2). D-type cyclins assemble 
with cdk6 or cdk4 as their catalytic partner in early/mid G1. Cyclin E mRNAs and 
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proteins begin to accumulate in late G1 and them associates with CDK2 (figure 3) 
(Coqueret, 2002; Ekholm and Reed, 2000).  The cyclin E/CDK2 complex is required for 
the transition from G1 into S, and its activation can be regarded as the molecular 
“threshold” that has to be overcome for a cell to pass the restriction point (Planas-Silva 
and Weinberg, 1997), which is an important checkpoint in the mammalian cell cycle. 
Passage through the restriction point commits the cell to enter S phase. The level of 
cyclin A increases at the G1/S transition phase and it forms complex with CDK2. Late in 
S-phase cyclin A associates with CDK 1. It is suggested that cyclin A is needed for 
ongoing DNA replication in S phase, and thus for the completion of S phase, but it also 
plays an essential role in the initiation of mitosis. Cyclin A and cyclin B in association 
with CDK1 act synergistically in the initiation of mitosis, but once in mitosis, it is the B-
type cyclins that seem to be the most important (Pines, 1995). Increased expression of 
both cyclins can be seen throughout mitosis. In order for the cell to exit mitosis, both 
cyclin A and cyclin B need to be degraded (Fung and Poon, 2005; McGowan, 2003). 
 
The expression of D-type cyclins depends on continuous mitogenic stimulation, 
suggesting that D-type cyclins provide a link between mitogen signaling and the cell 
cycle machinery. Cyclin E, A and B expressions are mostly independent of extracellular 
signaling and are regulated at the transcriptional or post-transcriptional levels, like cyclin 
D (Coqueret, 2002).  Figure 2 shows a typical pattern of cyclin expression during the cell 
cycle. The expressions of cyclin E, A, and B are periodically regulated throughout the 
cell cycle, whereas cyclin D expression is dependent on the presence of mitogen 
stimulation.    
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Figure 2.  The fluctuations of cyclins and p27Kip1 during the cell cycle. 
The expression of cyclins E, A and B is periodic, whereas D-type cyclins are expressed 
throughout the cycle in response to mitogenic stimulation. p27 levels are high in quiescent cells, 
fall in response to mitogen stimulation and remain low in proliferating cells (Sherr, 1996).                                      
 
ii) Regulation of CDK activity 
CDKs, either directly or indirectly, drive the cell-cycle transitions in all eukaryotic 
organisms. Due to their essential role in cell proliferation, they are subject to many levels 
of regulation in response to both intracellular and extracellular signals. This includes 
regulation of cyclin gene expression, post-translational modification of CDKs by 
phosphorylation-dephosporylation cascades, and by interaction with CDK inhibitors, the 
cip/kip-family of proteins (described in section 1.1.4). The first level of regulation is 
cyclin availability, and the fluctuation and regulation of these proteins is described in the 
previous section. 
 
The unstable cyclin proteins are degraded via the ubiquitin/proteasome pathway. The 
polypeptide ubiquitin form conjugates with the cyclin proteins, signaling to the cells that 
the proteins are ready to be disassembled. This ubiquitination process is dependent on 
phosporylation of the cyclin (Ekholm and Reed, 2000). When ubiquitin is attached to the 
proper proteins, they are degraded by the 26S proteasome, a multicatalytic protease. 
There are two complexes, the Skp-Cullin-F-box (SCF) and the anaphase-promoting 
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complex (APC), and they target specific cell cycle components at different points in the 
cell cycle. The SCF complexes function at the end of G1, throughout S and in early G2, 
whereas the APCs become active at the end of G2 (Peters, 1998).  
 
In addition to cyclin binding, the activity of CDKs is also regulated by phosphorylation 
and dephosporylation. In order to become active, cyclin/CDK-complexes are for instance 
phosphorylated on Thr 160 (in CDK2) by a CDK-activating kinase (CAK) (Morgan, 
1997).Whereas cyclin binding is sufficient to activate CDK activity as mentioned 
previously, the Thr160 phosphorylation induces a further 80-300 fold increased activity, 
probably through improved substrate binding. Cyclin/CDK complexes are also inhibited 
by phosporylation at two sites (Thr 14 and Tyr 15 in cdk2). Wee1 is the major kinase 
responsible for phosphorylation of Tyr15 and Thr 14, whereas the Cdc25 phosphatase 
family (consisting of Cdc25A, Cdc25B and Cdc25C) reverse these inhibitory CDK 
phosphorylations (Coqueret, 2002; Ekholm and Reed, 2000; Russell and Nurse, 1987). 
Interestingly the cdc25 proteins are themselves substrates of the CDKs. Cdc25A for 
instance is phosporylated and activated by cyclin E-CDK2, suggesting that a positive 






iii) Cell cycle inhibitors 
The activity of CDKs is regulated by the availability of cyclin subunits, the formation of 
cyclin/CDK-complexes, and by specific phosphorylation and dephosporylation (as 
described in section 1.1.1 ii). In addition, the activity of cdks in the different phases of the 
cell cycle is also governed by CDK inhibitors (CKIs). Two classes of CKIs has been 
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Ink4 family 
The Ink4 family is composed of four members: p15Ink4b, p16Ink4a, p18Ink4c and p19Ink4d. 
They are so named because of their ability to only inhibit the catalytic subunits of CDK4 
and CDK6 (Sherr and Roberts, 1999). The Ink4 inhibitors share a common structural 




There are three members of the Cip/Kip family: p21Waf1/Cip1, p27Kip1, and p57Kip2. They 
affect the activities of cyclin D-, E- and A-dependent kinases, and are able to bind both to 
cyclin- and CDK- subunits through a conserved N-terminal domain (Sherr and Roberts, 
1999). The Cip/Kip proteins are potent inhibitors of cyclin E- and A-dependent CDK2, 
but they may act as positive regulators of cyclin D-dependent kinases (Sherr and Roberts, 
1999). Due to their ability to bridge between cyclin and CDK (cyclinD/CDK4-
complexes) at low concentrations, Cip/Kip inhibitors can serve as chaperonins, which 
facilitate the attainment of an active conformation, and they also increase the nuclear 
translocation and the stability of D cyclins (LaBaer et al., 1997). These findings indicate 
that Cip/Kip inhibitors may work as positive, as well as negative regulators of the cell 
cycle. However there exists conflicting data regarding the role of Cip/Kip inhibitors as 
positive regulators of cell cycle progression (Olashaw et al., 2004). 
 
 
1.1.2 Cyclin D 
As mentioned in section 1.1.1, D-type cyclins are the first to be expressed after 
mammalian cells are released from quiescence as a response to mitogenic stimulation. 
They bind to either CDK4 or CDK 6, and promote G1 progression by inactivating the 
growth suppressive properties of the retinoblastoma protein (see section 1.1.3). The raise 
of cyclin D levels seen in early G1 also serve to titrate Kip/Cip proteins away from cyclin 
E/CDK2 complexes, thus accelerating cell cycle progression (Coqueret, 2002). D-type 
cyclin genes have been shown to be transcriptionally induced by c-Myc (Perez-Roger et 
al., 1999), AP-1 (Bakiri et al., 2000) and NF-κβ (Guttridge et al., 1999) which are all 
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transcription factors. Cyclin D is also regulated at the translational level which includes 
the PI3K-pathway (Muise-Helmericks et al., 1998). Mitogens have the ability to increase 
the rate of i.e. cyclin D1 translation by activation of the translation initiation factor eIF-
4E (Sonenberg and Gingras, 1998), while antiproliferative agents do decrease cyclin D1 
synthesis through inactivation of the same factor (Aktas et al., 1998). During the G1-
phase, cyclin D/CDK complexes assemble and get imported into the nucleus in a process 
which requires an active MAP-kinase pathway, and a molecular chaperone. During S 
phase D-type cyclin-CDK complexes are exported into the cytoplasm, and this is linked 
to the ubiquitin-mediated proteolysis (Pines, 1999).  
 
i) Cyclin D3 and cyclin D2 
In T-lymphocytes the major D-cyclins are D2 and D3, while D1 is not detected at all 
(Ajchenbaum et al., 1993). Cyclin D3 has been shown to be a key cyclin controlling T 
cell proliferation and apoptosis (Hleb et al., 2004). Among all D-type cyclin/CDK4- and 
CDK6 complexes, cyclin D3/CDK4 is most active in sequestering p27Kip1 away from 
cyclin E/CDK2, thereby allowing progression through G1(Zhang et al., 2005). 
Furthermore, Lea and coworkers suggest that there is a commitment point during G0 → 
G1 that controls activation into the cell cycle in T cells, and that activation of cyclin D2-
CDK6/4 is rate-limiting for progression through this point (Lea et al., 2003). They found 
that expression of cyclin D2 is induced by TCR/CD3-initiated signals, whereas cyclin D3 
expression seems to be primarily induced by IL-2 signaling. 
  
 
1.1.3 Regulation of the G1 to S transition (the RB pathway) 
i) pRB-dependent regulation of S-phase entry 
The transition through the different phases of the cell cycle is controlled by 
phosphorylation of specific targets of the cyclin/CDK-complexes. One of the best studied 
substrates of the G1 cyclin/CDK-complexes is the retinoblastoma protein (pRB), which is 
a member of the family of “pocket proteins”. The retinoblastoma gene (RB-1) was 
identified over a decade ago as the first tumor suppressor. The gene was initially cloned 
as a result of its frequent mutation in the rare pediatric eye tumor, retinoblastoma, where 
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a loss or mutation is seen in both alleles of the Rb-1 gene. Now it is thought to play an 
essential role in cellular regulation, where it has a key role in controlling the so called 
“restriction (R) point” in the G1 phase of the cell cycle (Harbour and Dean, 2000b; Hu et 
al., 1990). The restriction point, which occurs in mid-late G1 phase, subdivides G1 into 
two phases-early/mid G1 and late G1 phase (Zetterberg et al., 1995). The cells respond to 
extracellular signals in the period before the restriction point, and in the remainder of the 
cell cycle they are relatively, if not totally ignorant to such signals; thus once the cells 
have passed the R point, they seem to be committed to complete the remainder of their 
cell cycle program in an essentially automatic fashion (Planas-Silva and Weinberg, 
1997).  
 
The pRB primary structure is subdivided into several domains. The pocket region is 
composed of two highly conserved regions, A and B, which interact with each other 
along an extended interdomain interface which forms the central “pocket”. The A-box 
portion seems to be required for the stable folding of the B-box (Harbour and Dean, 
2000b; Lee et al., 1998). The A and B domains form a transcriptional repressor motif, and 
their protein binding capacity is regulated by cyclin dependent kinases (Muller and Helin, 
2000). Mutations affecting the retinoblastoma gene are frequently encountered in various 
human cancer forms (Harbour and Dean, 2000b; Horowitz et al., 1989).  
 
pRB function depends, at least in part, on interactions with the E2F family of 
transcription factors (Harbour and Dean, 2000b). E2F regulates the expression of several 
genes that encode proteins involved in cell cycle progression and DNA synthesis, such as 
cdc25, cyclin E and A and DNA polymerase α. E2F transcription factors can appear in 
free form as heterodimers containing a subunit encoded by the E2F gene family, and a 
subunit encoded by the DP family of genes. Alternatively it can form complexes 
containing E2F/DP heterodimers that are stably bound to a member of the pRB family of 
proteins (Dyson, 1998). 
 
The G1/S transition is regulated by the phosphorylation state of pRB. In quiescent cells, 
pRB is in a hypophosphorylated state, and it is this form of pRB that binds and inhibits 
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E2F, thus blocking the restriction point transition (Harbour and Dean, 2000b). The 
phosporylation of pRB is initiated by complexes containing D-type cyclins and either 
CDK4 or CDK6 in mid/early-G1 phase (figure 3). These complexes only initiate pRB 
phosphorylation, and do not drive it to completion. That seems to be accomplished by the 
CDK2-cyclin E complexes which are activated just before the cell passes through the R-
point and phosporylates pRB on additional sites. RB hyperphosporylation in late G1 
disrupts its association with various E2F family members, and this allows the coordinated 
transcription of several genes whose activitities are necessary for DNA synthesis 
(Coqueret, 2002; Harbour and Dean, 2000b; Hatakeyama et al., 1994; Resnitzky and 
Reed, 1995).  
 
Among the E2F-regulated genes are cyclins E and A, which both are required for the 
G1/S transition in normal cells. The capability of E2F to induce cyclin E, which in turn 
regulates CDK2 to maintain pRB phosporylation, creates a positive feedback loop that 
helps add to the irreversibility of the G1/S transition (Sherr and Roberts, 1999). Cyclin A- 
and B-dependent CDKs which become activated later during the cell cycle maintain RB 
in a hyperphosporylated form until the cells exit mitosis and RB is returned to a 
hypophosphorylated state in the next G1 phase (Sherr and Roberts, 1999).  
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Figure 3. Schematic illustration of the cell cycle machinery (see text for explanation). 
G0, G1, S, G2 and M refer to the quiescence, first gap, DNA synthesis, second gap and mitosis of 
the cell cycle, respectively. R point indicates the restriction point in G1. D, E, A, B and P indicate 
cyclin D, cyclin E, cyclin A, cyclin B and phosphate group, respectively.                          
                                   
 
ii) pRB-independent regulation of S-phase entry 
Evidence suggests that cyclin E may be able to promote S phase entry via pathways that 
do not involve pRB. Lukas and co-workers have demonstrated that cyclin E can induce S-
phase without activation of the pRB/E2F pathway, and that cyclin E can act downstream 
from Rb/E2F, suggesting that there are additional substrates for cyclin/CDK2 complexes 
(Lukas et al., 1997). Furthermore, expression of cyclin E or transcriptionally active Myc 
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can rapidly induce DNA synthesis in cell lines where E2F activity is blocked by 
expression of constitutively active pRB mutant. The effect of Myc requires both cdc25A 
phosphatase (mentioned in section 1.1.1ii) and cyclin E, both known transcriptional 
targets of Myc (Santoni-Rugiu et al., 2000). These results suggest that cyclin E also is a 
target of a G1/S-promoting mechanism different from the pRB pathway, where Myc is 
involved.  
                                                   
 
1.2 T lymphocytes 
The immune system comprises cells in blood, lymph, bone marrow, thymus, spleen and 
lymph glands. Broadly outlined, the immune system can be divided into two parts; i) non-
adaptiv/ innate immunity and ii) adaptive immunity. Innate immunity provides the first 
line of defense against foreign agents, and is not dependent of previous exposure to 
antigens. While cells in the innate immune system lack specificity against the foreign 
“invaders”, cells in adaptive immunity are characterized by having both immunologic 
specificity and immunological memory. Lymphocytes, i.e. T cells and B cells, constitute 
the adaptive immune system. The cellular part of the adaptive immune response is 
mediated by T cells, whereas the humoral immune response is mediated by B cells which 
produce specific antibodies against foreign agents.  
 
T cells are derived from bone marrow stem cells. Immature precursor T cells leave the 
bone marrow and migrate to the thymus. Here they undergo gene rearrangement which 
produces cells with unique antigen receptor expression and develop into mature T cells 
capable of responding to foreign antigens. In thymus only thymocytes with weak 
specificity for “self” Human Leukocyte Antigen (HLA)-molecules survive the first 
positive selection process. Thus, thymocytes that react too strong with “self” HLA-
molecules are killed by apoptosis during a process called negative selection (Lea, 2000).  
 
1.2.1 TCR/CD3-signaling 
It is well known that T cells need two signals in order for them to be activated and 
proliferate. First, antigenic stimulation of the TCR/CD3 complex drives the cells from 
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their quiescent state (G0) into the G1 phase of the cell cycle (Lea et al., 2003). Second, 
the binding of IL-2 to its high affinity receptor leads to G1-to S-phase transition and thus 
proliferation (Nelson and Willerford, 1998).  
 
The T cell antigen receptor (TCR) is triggered in response to foreign peptides presented 
on molecules encoded within the major histocompatibilty complex (MHC) on antigen-
presenting cells (APCs) (Schrum et al., 2003). The T cell receptor (TCR) consists of two 
heterodimeric αβ or γδ polypeptide chains. However, most T cells (in mice and humans) 
express αβ TCRs (Schrum et al., 2003). The TCR is tightly linked to a CD3 complex 
which consists of three invariant polypeptides γ, δ and ε and two additional homodimeric 
(ζ- ζ) or heterodimeric (ζ-η) subunits. This CD3 complex transduces the activation signal 
generated by ligand binding to TCR (Mustelin and Tasken, 2003).  
 
 




Figure 4.  The schematic illustration of the mechanism behind the TCR/CD3-complex-
mediated activation of the cell (see text for details). The ITAM-sequences are marked in red 
(Lea, 2000).  
 
There are also other accessory molecules that are involved in T-cell activation. The CD4- 
and CD8-co-activators are central in T- lymphocytes activation. CD4+ T-cells only react 
with antigens bound to HLA-class II, whereas CD8+ T-cells recognize antigens in 
complex with HLA-class I-molecules. The binding between the CD4/CD8- and HLA-
molecules are relatively weak, but strong enough to have an important functional 
influence, because they both are associated with p56lck, a protein tyrosine kinase, which 
will be discussed later. CD28 is another important interaction molecule involved in the 
activation of T-cells.  It has two ligands, B7.1 (CD80) and B7.2 (CD86), presented on the 
membrane of APCs. When a T cell with its TCR binds to an APC with B7-molecules on 
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the surface, then the binding between B7 and CD28 will result in signal 2. This signal is 
necessary in order for T cells to proliferate and mature into effector cells, which will be 
described in section 1.2.2 (Lea, 2000). 
 
A key initiating event in T cell activation is the increased phosphorylation of 
immunoreceptor tyrosin-based activation motif (ITAM) tyrosines in the TCR subunits. 
These ITAMs are found mainly in the Src family tyrosine kinases p56lck, but also p59fyn 
(Mustelin and Tasken, 2003). Phosphorylation of the ζ chain recruits the tyrosin 
kinaseZap-70(Zeta Activating Protein), but subsequent phosphorylation of Zap-70 by Lck 
is needed to activate the kinase (see figure 5). Once activated, Zap-70 phosphorylates a 
membrane bound adapter protein, LAT (Linker for Activation of T-cells). LAT recruits 
several proteins, for instance downstream Src homology 2(SH2) and SH3 domain-
containing proteins. The recruitment of these proteins activates various signalling 
pathways which end up in the nucleus and result in activation of transcription factors 




1.2.2 IL-2R and IL-2 signaling 
The activation of CD4-+ T cell by antigen makes it increase in size, and it becomes a so-
called blast cell. About six to eight hours after the activation, changes in cell surface 
molecules can be shown. A new activation antigen, CD25, the important α- polypeptide 
chain for the high-affinity receptor IL-2, emerges. After about twelve hours, activated T-
cells produce and secrete IL-2, which will be bound to the IL-2 receptor (IL-2R). The 
binding of IL-2 to the IL-2R will result in CD4-+ T cell proliferation (Lea, 2000).  
 
The high-affinity IL-2 receptor comprises three subunits, the α, β and γ-chains (Gesbert et 
al., 1998). Resting T cells generally express low to intermediate levels of the β and γ 
subunits and no, or very low, levels of IL-2R- α on their cell surface. Upon T cell 
activation, the cell surface levels of IL-2R- α are rapidly increased, while the surface 
levels of the β and γ subunits are only moderately increased. Both the α- and β-chain can 
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bind to IL-2, but only with low affinity. However, physiological IL-2 signaling is 
believed to occur through binding of IL-2 to the high affinity, heterodimeric (αβγ) IL-2 
receptor (Lea, 2000). The α-chain is responsible for IL-2 binding and internalization, and 
does not appear to be involved in intracellular signaling (Gesbert et al., 1998). 
 
None of the chains in the IL-2 receptor complex have enzymatic activity, so the 
activation signals are transmitted into the cell by recruiting protein tyrosine kinases (the 
PTK Syk of the Syk/ ZAP family, and Jak1 and JAK3 of the Janus kinase family) to the 
complex (Gesbert et al., 1998). In the presence of IL-2, the three subunits of the IL-2 
receptor are brought together (see figure 5). Thereby, tyrosine kinases, such as Janus 
kinase 1 (JAK1) and Janus kinase 3 (JAK3), which associate with β and γ subunits, 
respectively, are also brought together, and are thought to activate each other through 
reciprocal phosporylation (Lea, 2000).   
 
JAK activation results in the phosphorylation of several tyrosine residues on the β 
subunit, which serve as docking sites for signaling molecules. There are for instance two 
independent pathways that are initiated from these docking sites, and which are believed 
to play major roles in IL-2-mediated proliferation and survival. These are the JAK/STAT 
pathway and the MAPK/ERK pathway (Ellery and Nicholls, 2002; Gesbert et al., 1998; 
Lin and Leonard, 1997). Furthermore, the PI3K-pathway is another signaling pathway 
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Figure 5. Schematic illustration of the signaling pathways associated with IL-2R β and /or γ-
subunit which are known to be activated by IL-2. PTKs represent the various protein tyrosine 
kinases mentioned in the text. The broken lines and question mark indicate signaling pathways 
not fully understood, and they are therefore not described further in the text. The figure is 




i) The JAK/STAT pathway and the MAPK/ERK pathway 
Activation of the JAK/STAT-pathway results from docking of STAT5 to Y392 and Y510 
of the β subunit (Lin and Leonard, 1997). After docking, this transcription factor is 
phosphorylated by JAKs, which results in their homodimerization and activation. The 
STAT5 homodimer translocates to the nucleus, where they will regulate transcription of 
genes which are necessary for proliferation and differentiation of T cells to effector cells 
(see figure 5) (Benczik and Gaffen, 2004; Gesbert et al., 1998). 
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In general, the MAPK/ERK pathway takes part in cell proliferation and inhibition of 
apoptosis (Chang et al., 2003). 
 
The adaptor protein Shc is first docked to Y338 of IL-2R-β (Lin and Leonard, 1997). Shc 
recruits proteins that activate the Ras-Raf-MAP- and PI3-Akt-kinase pathways (see next 
section), respectively.  Then, the formation of a Shc-Grb-Sos trimer occurs. Shc and Grb2 
connect the receptor to Son of Sevenless (sos), a guanine nucleotide exchange factor, 
which in turn tranduces a signal to Ras, a small GTP binding protein. Thereafter three 
signaling molecules are activated: Raf (MAPKKK), mitogen activated protein kinase 
kinase (MEK) 1/2 (MAPKK) and MAPK1/2 (see figure 5). The phosphorylated ERK 
dimer can regulate targets in the cytosol and the nucleus by activating other protein 
kinases such as ribosomal S6 kinases and Mnk, which in turn phosporylate proteins 
involved in chromatin remodeling, or transcriptions factors such as for example c-Jun, c-
Fos and c-Myc (Benczik and Gaffen, 2004).   
 
In addition to the STAT5 and Shc pathways, activation of another STAT transcription 
factor, STAT3, may also be involved in IL-2-mediated proliferation (Ellery and Nicholls, 
2002). STAT3, which is constitutively associated with IL-2R-β, is also tyrosine 
phosporylated by JAKs. Later it is phosphorylated on a serine residue by ectracellular 
regulated kinase (ERK). Both phosphorylation events are essential for maximal STAT3 
transcriptional activity (Wen et al., 1995).  
 
 
ii) PI3K pathway 
The PI3K pathway is so far the best characterized pathway downstream of the IL-2R. 
The phosphateidylinositol-3-kinase is a family of lipid and serine/threonine kinases.  
Phosphatidylinositol (PtdIns) consists of a glycerol backbone to which two fatty acids 
and an inositol 1-phosphate group are attached (Figure 8). A phosphorylated PtdIns is 
called a phosphoinositide (PI). All PIs reside in membranes, where they interact with a lot 
of cellular proteins via unique lipid-binding motifs, such as pleckstrin homology (PH) 
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domains, Src homology-2 (SH2) domains and phospotyrosine-binding (PTB) domains 




Figure 6.   Chemical structure of phosphatidylinositol. The inositol head group is localized in 
the cytosol, whereas the fatty acid tails (R1 and R2) lie within the inner leaflet of lipid bilayer. 
 
 
 PI3K family members are divided into four classes (class Ia, Ib, II, III) based on 
sequence homology and substrate specificity, but it is mainly the PI3K molecules from 
class Ia that become activated in response to cytokine signaling. Class Ia PI3Ks are 
heterodimers which are composed of two subunits: a catalytic subunit with a molecular 
weight of 110 kD (p110α, p110β or p110δ) and a regulatory subunit (p85α, p55α, p50α, 
p85β, or p55γ). The activation of class Ia PI3K is induced when tyrosine kinases 
phosporylate membrane proteins, and receptors at residues that are located within a 
special Tyr-X-X-Met (YXXM) motif. This in turn serves as a docking site for the SH2 
domain of a regulatory subunit of PI3K, thus bringing the catalytic subunit in proximity 
with the membrane and its lipid substrates. This step then activates the p110 kinase, 
which is otherwise inhibited in the p85-p110 complex (Benczik and Gaffen, 2004). 
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PI3K can connect with the IL-2R complex via Shc-Grb2-Gab2, and IL-2 stimulation of T 
cells results in a rapid activation of PI3K and phosphatidylinositol (3,4,5) triphosphate 
(PIP3) (Benczik and Gaffen, 2004). 
 
Downstream of PI3K, the protein kinase Akt/PKB is recruited to the membrane-anchored 
PIP2 and PIP3 (lipid substrates of PI3K). To be fully active, Akt/PKB needs to be 
phosporylated at two sites (Ser 473 and Thr 308). PDK 1 (phosphoinositode-dependent 
protein kinase) is the upstream kinase that targets Thr 308 (Benczik and Gaffen, 2004), 
whereas the kinase responsible for phosphorylation of Ser 473 remains unidentified. 
 
 
1.2.3 Regulation of the T cell cycle machinery by IL-2/IL-2R 
TCR-CD3 signals drive resting T cells from their quiescent, G0 state, into the cell cycle 
(Firpo et al., 1994). However, in the absence of IL-2, S phase entry does normally not 
occur (Firpo et al., 1994; Modiano et al., 1995). Thus, the CDK2 complexes are not 
generated, and the cells are arrested in G1, due to the inability of TCR/CD3 signals to 
down-regulate the expression of p27Kip1. In the presence of IL-2, will p27 Kip1 protein 
levels become strongly downregulated, CDK2 becomes active, and the cells are driven 
into S phase (Firpo et al., 1994; Kwon et al., 1997). Interestingly, the protein levels of 
another CKI, p21Cip1, are increased by IL-2 (Nourse et al, 1994; Firpo et al, 1994), which 
can be explained by the dual role of p21 as both a CDK activator and inhibitor (see 




1.3 Cell death 
1.3.1 Apoptosis and necrosis 
In general, cells die through one of two alternative pathways: i) apoptosis, a programmed 
and highly ordered form of cellular destruction, or ii) necrosis, a passive and unregulated 
form of cell death. Apoptosis is an active process which requires protein synthesis for its 
execution. Characteristic morphological features like cell shrinkage are seen in cells 
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which undergo apoptosis (Walker et al., 1988). The most evident changes occur in the 
nucleus, which includes chromatin condensation and nuclear shrinkage, as seen in figure 
7 (Walker et al., 1988). A characteristic feature is also the formation of apoptotic bodies 
(Walker et al., 1988). The morphological changes which appear are a result of molecular 
alterations, such as DNA and RNA cleavage, post-translational modifications of nuclear 
proteins, and proteolysis of several polypeptides residing in the nucleus (Martelli et al., 
2001). 
 
A hallmark of apoptosis is the cleavage of DNA into 200 bp fragments, which can be 
detected either by electrophoreses, or by flowcytometric analysis using the TUNEL 
method. Apoptosis is vital for differentiation, morphogenesis, development and 
homeostasis of multicellular organisms, and it is the most usual form of physiological cell 
death. Apoptosis plays a major role for the maturation of the immune system, and can 
therefore be involved in disorders that origin in the immune system, for example AIDS 
where mature CD4+ -cells dies, and autoimmune disease (Martelli et al., 2001). For 
instance, genetic analysis indicates that deficiencies in serum proteins or receptors that 
mediate clearance of apoptotic cells increase the risk of autoimmunity (Cline and Radic, 
2004). 
 
In mammals, diverse death stimuli induce apoptosis by activating the caspase family of 
cyctein proteases (Breckenridge and Xue, 2004). The caspases are activated in a cascade-
ordered manner by two different main pathways, one being mediated via death receptors, 
and the other process inducing mitochondria (Breckenridge and Xue, 2004; Green, 2005; 
Kroemer and Martin, 2005). Caspases are proteolytic enzymes, and when inactive they 
lay dormant in the cell as zymogens.  
It is generally believed that the Bcl-2 family of proteins and sometimes the caspases 
themselves governs the release of apoptogenic factors from the mitochondria. Bcl-2 is a 
proto-oncogene; the normal cellular gene from which an oncogene has been derived. Bcl-
2 family proteins can be subdivided into three main classes on the basis of their functions 
and the number of Bcl-2 homology (BH) domains present.  Class 1 is antiapoptotic and 
contains four BH domains (BH1 to BH4). Bcl-2 and Bcl-xL belong to this group. Bak 
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and Bax are members of the class 2 proteins which are pro-apoptotic and they possess 
three BH domains (BH1-BH3). The BH3-only pro-apoptotic members such as Bid and 
Bim share homology only within the BH3 domain, and they belong to the third class 
(Breckenridge and Xue, 2004). 
 
It is generally accepted that distinct apoptotic signals first converge upon different BH-3-
only proteins, which upon activation deliver the death signals to mitochondria by 
engaging Bax/Bak or Bcl-2/Bcl-xL. BH-3-only proteins are activated for instance by 
post-translational modifications, such as caspase-8 mediated cleavage of Bid into an 
activated, truncated Bid (tBid). Bax and Bak mediate permeabilization by forming pores 
in mitochondria. The formation of tBid amplifies initiator caspase signals by inducing the 
release of proteins such as cytocrom c (cyt c) (Breckenridge and Xue, 2004). When cyt c 
is released from mitochondria, it interacts with APAF-1 and procaspase-9. This complex 
favors the activation of caspase-9 which, when activated, cleaves and activates caspase-3 
which in turn cleaves other caspases. These molecules then cleave substrates in the cell to 
produce the cellular and biochemical events we see in apoptosis (Green, 2005). 
 
It is suggested that Bcl-2 anti-apoptotic proteins may function both by sequestering active 
BH-3-only proteins and by restricting Bax/Bak oligomerization, thus setting an activation 
barrier for the induction of apoptosis and limiting inappropriate cell death. During 
apoptosis, the anti-apoptotic activity of Bcl-2 is probably overcome by simultaneous 
activation of distinct classes of BH3-only proteins, some of which bind to and inactivate 
Bcl-2. This sets BH-3-only proteins free to activate Bax/Bak (Breckenridge and Xue, 
2004; Green, 2005).   
 
Necrosis is another type of cell death, and it is a result of irreparable cell injury, often 
caused by stimuli that damage cell membranes or inhibit energy production in the cell 
(Endresen and Aarbakke, 1992). Necrosis is characterized by swelling of the cell, and 
when the cells burst, this leads to lysis of the cells (see figure 7). The cell content which 
leaks out extra-cellularly causes inflammation. Random DNA degradation, and not DNA 
fragmentation as in apoptosis, is observed in necrotic cells (Walker et al., 1988). There is 
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increasing awareness that these two pathways, apoptosis and necrosis only represent the 
extreme ends of a variety of possible morphological and biochemical deaths (Martelli et 
al., 2001).   
A B
 
Figure 7. The morphology of necrosis and apoptosis. The typical morphological features of 
apoptosis (A) and necrosis (B) are shown. Adapted from Duvall and Wyllie, 1986. 
 
 
1.3.2 T cell death: AICD and ACAD 
Resting T cells are reasonably resistance to apoptosis, partly due to their high expression 
of anti-apoptotic Bcl- 2 proteins (Salmon et al., 1994). T cells respond to antigen- 
stimulation through a process of activation, division and differentiation resulting in a 
rapid accumulation of a large amount of activated effector T cells. Once T cells are 
activated, they become much more susceptible to die. This is logical, since resting T cells 
need to stay alive for a long time in order to maintain the body`s repertoire of antigen-
scanning. Activated T cells, however, need to die at some point; either because they are 
not needed, as when the immune system “shuts” down after the antigen has been cleared, 
or because they are continuously activated by self-antigens and therefore should be 
deleted. Following a peak of expansion, their numbers begin to decline rapidly through a 
process termed the contraction phase. During this decline some of the T cells migrate to 
nonlymhoid tissues, where they reside as memory T cells, but most of the activated T 
cells disappear through apoptosis (Hildeman et al., 2003).  
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 Two distinct pathways have been shown to be responsible for the death of activated T 
cells in vivo: activation-induced cell death (AICD) and activated T cell autonomous death 
(ACAD) (Hildeman et al., 2002; Hildeman et al., 2003). AICD is initiated by the 
activation of death receptors; Fas, but also by TNFα, when T cells encounter repeated 
self-antigen. Once these receptors are engaged, they activate downstream pathways that 
lead to caspase activation and cell apoptosis. In contrast, ACAD proceeds after a single 
exposure to antigen (during the termination of an immune response) through a 
mitochondrial pathway and is driven by intrinsic (i.e. without the involvement of other 
cells) signals in the activated T cell that are independent of death receptors to induce 
apoptosis (Hildeman et al., 2002; Hildeman et al., 2003). This cell death is initiated by an 
activation-induced alteration in the balance between pro- and anti-apoptotic members of 
the Bcl2 family, which leads to mitochondria-induced apoptosis. ACAD is responsible 
for the death of the majority of T cells which responds to foreign antigen (Hildeman et 
al., 2002).  
 
 
1.4 Vitamin A 
1.4.1 Vitamin A and its physiological role 
Vitamin A is defined as substances with the same biological effect as retinol. Vitamin A 
(retinol and its derivatives) is involved in various biological processes, such as growth, 
reproduction, cellular differentiation, embryonic development and visual response. 
Vitamin A is also imortant for normal immune function, which will be discussed in a 
later section (see section 1.4.3). 
 
Vitamin A is a nutrient and derives from carotinoids in plants and retinyl esters in animal 
tissues. Under normal dietary conditions vitamin A is present at relatively high 
concentrations (3µM) in plasma and therefore potentially available to all cells in the body 
(Blomhoff et al., 1990). The major source of retionids for target cells in vivo is retinol 
bound to retinol-binding protein or retinylester in chylomicron particles (Blomhoff, 
1994). However, inside target cells retinol can also be oxidized to the active metabolite 
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retinoic acid (RA). Several naturally isoforms of RA has been detected, which includes 
all-trans RA and 9-cis RA. They are the most active retionids in most cell types.  
                                                                           
                                                    
Figure 8. Structure of 9-cis retinoic acid          Figure 9. Structure of all-trans retinoic acid 
 
 
1.4.2 General mechanism of action of vitamin A 
Vitamin A and its metabolites are signaling molecules that act through interaction with 
two families of retionid receptors, retinoic acid (RAR α, β and γ) and retionid X (RXR α, 
β and γ) receptors. These receptors belong to the superfamily of nuclear receptors (NRs), 
including various receptors as those for steroids and thyroid hormones, and vitamin D3. 
The NRs act as ligand-inducible transcription factors (Escriva et al., 1997).  
 
RARs and RXRs form heterodimers, whereas RXRs form homodimers, as well as 
heterodimers with other members of the nuclear receptor family. RXRs may for example 
form heterodimers with vitamin D receptors, thyroid receptors and peroxisome 
proliferators-activated receptors (PPAR) (Kliewer et al., 1992). 
      
 
atRA preferentially binds to and thereby activates RARs, whereas 9-cis RA activates both 
RARs and RXRs. RXRs bind and are activated by 9-cis RA with Kd values of 1.4 to 2.4 
nM, and RARs  activate 9-cis RA with Kd values of  0.2-0.7 nM (Roy et al., 1995). RAR-
, but not RXR-ligation is sufficient to activate RAR/RXR heterodimer. In addition, 
simultaneous ligation of both RAR and RXR acts synergistically on RAR/RXR 
transcriptional activity (Bastien and Rochette-Egly, 2004; Gronemeyer and Miturski, 
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2001). More than 100 genes have been found to be directly regulated by RA-mediated 
activation of RAR/RXR. Furthermore, RA can indirectly regulate the expression of 
several hundred other genes (Balmer and Blomhoff, 2002). Although, the RAR/RXR-
pathway has been shown to be the major signaling pathway, other pathways might also be 
included. First, RXR/RXR may regulate genes, but this has not been proven in vivo 
(Mangelsdorf et al., 1991). Second, although RXR usually acts as a “silent” partner with 
other nuclear receptors than RAR (mentioned above), it may act as a ligand-dependent 
transcriptional regulator in some circumstances (Leblanc and Stunnenberg, 1995). Third, 
RA may also function independent of RAR/RXR (Konta et al., 2001; Radominska-
Pandya et al., 2000). Konta and coworkers examined the role of at-RA in apoptosis and 
whether RAR and RXR are required for the at-RA mediated suppression of c-fos/c-jun 
expression and c-Jun N-terminal kinase (JNK). They demonstrated that suppression of 
JNK activation by at-RA was mediated by neither RAR nor RXR. The authors suggest 
that the suppressive effect of at-RA in this study might be mediated by other types of 
receptors. For instance, it has been reported that at-RA can bind to insulin-like growth 
factor-II receptor and enhances the primary effect of this receptor (Kang et al., 1999). It 
has also been found that at-RA can modulate the activity of protein kinase C by direct 
binding to the retinoic acid binding site of protein kinase C-α (Radominska-Pandya et al., 
2000). Finally, retinoylation (acylation by RA of proteins) is another mechanism by 
which RA may act on cells (Takahashi and Breitman, 1994). 
 
 
Figure 10. The mechanism behind retinoic acid regulated gene expression. Retionic acid 
binds to RAR which dimerize with RXR and RAR-RXR heterodimer bind to RARE (retinoic acid 
response element) (Blomhoff, 1994). 





1.4.3 Vitamin A and immunity 
It is well established that vitamin A plays an essential role for normal immune function 
(Blomhoff and Smeland, 1994; Nauss, 1986; Ross, 1992; Semba, 1999; Sommer, 1993a; 
Stephensen, 2001; Villamor and Fawzi, 2005). This conclusion is based on numerous 
studies in animals and humans, studying the effects of vitamin A deficiency and 
supplementation. 
 
Vitamin A deficiency in humans is associated with increased morbidity and mortality 
from infections, such as for example respiratory-, diarrheal-, and -gastrointestinal 
infections (Semba, 1999; Sommer, 1993b). Deficiency can be a result of too low dietary 
intake of the vitamin and /or from severe or chronic infectious diseases, which causes 
depletion of vitamin A through several mechanisms (Stephensen, 2001). Clinical trials 
suggest that vitamin A-supplementation reduces morbidity and mortality from different 
infectious diseases, such as measles, diarrhoeal disease, measles-related pneumonia and 
human immunodeficiency virus infections (Semba, 1999; Semba et al., 2005). However, 
how vitamin A improves immune function against these infections is poorly understood 
(Semba, 1999). Vitamin A as an immunostimulating agent is further proven by studies 
where vitamin A supplementation increased the efficiency of several vaccines, such as 
diphtheria, measles and polio type 1 (Bahl et al., 2002; Benn et al., 2002; Ross, 1992). In 
addition, vitamin A, either in the form of retinol or its metabolite, retinoic acid, has been 
shown to stimulate the rejection of certain immunogenic tumors (Ross, 1992). 
 
Most of our knowledge on how vitamin A influence the immune function come from 
studies where the immune system of vitamin A-deficient  (VAD) or normal animals has 
been challenged (see review from (Blomhoff and Smeland, 1994; Nauss, 1986; Ross and 
Stephensen, 1996; Stephensen, 2001). From these studies it is obvious that vitamin A can 
affect components of all parts of the immune system. For instance, vitamin A can fortify 
the innate immune system by stimulating natural killer cells and macrophages, and in 
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addition vitamin A is involved in the regeneration of mucosal barriers (Blomhoff and 
Smeland, 1994; Ross and Stephensen, 1996; Stephensen, 2001). Also, both humoral and 
cellular immune responses can be stimulated by vitamin A (Blomhoff and Smeland, 
1994; Stephensen, 2001)).  
 
 
1.4.4 Effect of vitamin A on isolated T lymphocytes 
Previous studies on the role of vitamin A in T cells have been conflicting, since they have 
indicated that vitamin A could enhance, inhibit, or have no effect on T cell proliferation 
(Blomhoff and Smeland, 1994; Fish et al., 1981; Nauss, 1986). However, these 
conflicting data could in part be explained by differences in concentration of vitamin A 
and the purity of the T cell (Blomhoff and Smeland, 1994; Fish et al., 1981; Nauss, 
1986). It was found that while concentrations of atRA above 10 µM was inhibiting, lower 
concentrations (in this study 0.1-10 µM) enhanced PHA- induced proliferation of bovine 
lymph node cells (Mastro and Pepin, 1982). In another study it was found that while 
atRA (at 50nM-5 µM concentrations) enhanced both TPA- and PHA-induced 
proliferation of highly purified human peripheral blood mononuclear cells, RA had 
various and inconsistent effects on unpurified peripheral blood mononuclear cells 
(PBMCs) (Valone and Payan, 1985). Various in vitro studies in the 1980`s and 1990`s 
using different T cell-activating stimuli indicated that RA or retinol can stimulate the 
proliferation of for example: mouse spleen cells (Jiang et al., 1992), antigen-specific 
mouse T cell clones (Friedman et al., 1993), human thymocytes (Sidell and Ramsdell, 
1988)and human PBMCs (Allende et al., 1997). RA did not induce T cell proliferation by 
themselves in any of those studies, indicating that RA has a co-stimulatory role in T cell 
proliferation. 
 
Recently, we have demonstrated that purified CD4+ human T cells are stimulated by RA 
(Ertesvag et al., 2002), and that apoptosis is prevented (Engedal et al., 2004). 
 
Except from studies in our own group, the molecular mechanism(s) on how vitamin A 
might stimulate T cell proliferation has been poorly studied. We observed that the effect 
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of RA on both T cell proliferation and on apoptosis, at least in part was dependent on the 
ability of RA to increase IL-2 production in human T cells (Engedal et al., 2004; Ertesvag 
et al., 2002). It has also been reported that RA increase the expression of IL-2 receptors in 
murine splenic T lymphocytes (Jiang et al., 1993) and in human thymocytes (Sidell et al., 
1993). Furthermore, Sidell and coworkers have studied the effect of retinoic acid on the 
expression of IL-2Rα- and-β in Hut78 cells (a mature T cell-line) and found that RA can 






















   29 
 
2. AIMS OF THIS THESIS 
Vitamin A has been shown to be important for an optimal function of the immune 
system. Numerous studies in man and in animal models have revealed that vitamin A 
deficiency leads to increased risk of infections, and that supplementation of vitamin A to 
such individuals restores the immune function (Blomhoff and Smeland, 1994; Ross, 
1992; Semba, 1999; Sommer, 1993a; Stephensen, 2001; Villamor and Fawzi, 2005). It is 
not, however, clear how vitamin A stimulates the immune system. In our lab we have for 
several years studied the role of vitamin A on purified populations of B-and T-
lymphocytes in vitro. We have found that proliferation of both human and murine B-cell 
precursors is inhibited by physiological levels of the vitamin A metabolite retinoic acid 
(RA) (Blomhoff et al, 1992; Fahlman et al; 1995; Naderi and Blomhoff). Also naive 
human B-cells are inhibited by RA (Fahlman et al, 1995), whereas the apoptosis in these 
cells is prevented (Lomo et al., 1998). In contrast to the effects on B-cells, we have 
shown that the proliferation of normal human T-lymphocytes is stimulated by RA 
(Ertesvag et al., 2002), and that also in T-cells, the apoptosis is prevented (Engedal et al., 
2004). Furthermore, we have recently demonstrated that the effects of RA on both 
proliferation and apoptosis in T-cells are mediated via induced production of IL-2 
(Engedal et al., 2004).  
 
The overall purpose of the present study has been to elucidate if RA, independent of its 
ability to induce IL-2, also is able to enhance IL-2 mediated signaling in T-cells. We have 
had the following specific aims: 
1. Determine whether RA enhances IL-2 mediated proliferation    
If so, 
2. Determine whether RA affects IL-2 mediated changes in the cell cycle machinery. 
3. Understand the mechanisms whereby RA may stimulate IL-2 mediated cell signaling. 
4. Determine whether the effects of RA on IL-2 mediated signaling involves the nuclear 
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α-32P dCTP (10mCi/ml) Amersham 






Bovine Serum Albumin Sigma 
β-mercaptoethanol Sigma 
Bio-Rad Protein assay Bio-Rad 
Bromophenol blue Bio Rad 




Ethidium bromide (EtBr)  Sigma 













LymphoprepTM Fresenius Kabi Norge 
Methanol BDH 
MicroscintTM PACKARD 
Molecular weight standard Bio Rad 
MOPS MULTI-CORETMBuffer (10X) Promega 
Non fat dried milk Nestle Molico 
NP-40 Sigma 
OPti-fluor® PACKARD 
Penicillin Streptomycin Gibco/ BRL 
Pepsin Sigma 
PMSF Sigma 
Ponceu S Sigma 
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Precision Protein Standard Broad Range Bio-Rad 
Propidium Iodide Sigma 
Ro-41-5253 Gift from Dr M Klaus (Hoffman-La Roche, 
Basel, Switzerland) 
RPMI 1640 Gibco/ BRL 
Sodium acetate Prolabo 
Sodium azid (NaN3) Merck 
Sodium chloride (NaCl) BDH  laboratories 
Sodium dodecyl sulphate (SDS) Sigma 
Sodium fluoride (NaF) Merck 
Sodium hydroxide Merck 
Sodium orthovandate (Na3VO4) Sigma 
Sodium pyruvate (Na-P) Sigma 
Sodium tetra borate  Merck 
Retionic acid Sigma 
RNasin Promega 
TEMED Bio-Rad 
[3H]-thymidine Amersham Biosciences 
Tris base Angus Buffers & Biochemicals 
Triton X-100 Sigma 
TTNPB Sigma 
Tween20 Sigma 




Anti bodies  
Anti-CD3 Purified from OKT-3-producing 
hybridoma cell-culture supernatants 
Anti CD4 beads Miltenyi Biotec 
Cyclin A (C-19) rabbit polyclonal IgG Santa Cruz Biotechnology 
Cyclin D3 ((DSC-22) MBL 
Cyclin D2 (C-17)   rabbit polyclonal IgG Santa Cruz Biotechnology 
Cyclin E (HE 12) mouse monoclonal IgG Santa Cruz Biotechnology 
FITC-conjugated anti-BrdU PharMingen 
Goat anti –mouse IgG Bio-Rad 
Goat anti-rabbit IgG Bio-Rad 
p21 (C-19)rabbit polyclonal IgG Santa Cruz Biotechnology 
p27 (C-19) goat polyclonal IgG Santa Cruz Biotechnology 
Anti phospho-STAT3 (Tyr705, #9135) Cell signalling Technology 
pRB (14001A) Mouse monoclonal IgG Pharmingen 
Phospho-STAT3 (Ser727, #9134) Cell signalling Technology 
STAT3 (#9132) 
 
Cell signalling Technology 
Kits  
ECL+Western Blotting detection system Amersham Pharmacia Biotech 
Mega prime DNA labelling system Amersham 
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Cyclin D3 vector (pEF1-HisC) 
 








Agarose electrophoresis apparatus Hoefer 
Beckman OptimaTM LE-80K 
Ultracentrifuge 
Beckman 
Buffy coat Ullevål University Hospital 
CastAway Gel Dryer Stratagene 
CastAway® Precast Sequencing Gel Stratagene 
Cell culture flasks  NUNC 
Cell culturing plates (24- and 96-well flat-
bottomed microtiter plates) 
BD; Falcon 3072 and 3047 
Centrifuge tube (15ml and 50 ml) Merck 
CO2-incubator NuaireTM 
Coulter® Microdiff 18 (Cell counter) Dan Meszantsky 
Disposable syringe (1 or 2ml) Becton Dickinson 
Eppendorf tubes (micro tubes 1,5 ml) Axygen Scientific 
Erlenmeyer bottles  Pyrex 
FaCSCaliber Becton Dickinson 
Falcon tubes (5ml) Beckton Dickinson 
Filtermate 196 harvester Packard 
21G needles Becton Dickinson 
Geiger counter Laborel 
GladpackTM Andvord 
Heating block Dan Meszantsky 
Hybaid hybridization oven Hybaid 
HybondTM ECL TM Nitrocellulose 
membrane 
Amersham Pharmacia Biotech 
HybondTM-N Amersham LIFE SCIENCE 
Hybridization cylinder Hybaid 
HyperfilmTM MP Amersham Pharmacia Biotech 
Incubator Shaker New Brunswick scientific co 
Kodak X-Omatic cassette Kodak 
Light microscope equipped with a 40x 
objective 
Nikon 
LS 6500, Multi-purpse scintillation counter Beckman 
Magnet for cell culture flask Self-made 
Micro tube (0,2 ml) Abgene 
Micro tube (1,5ml) Axygen Scientific 
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Microwave oven Sharp 
Mini protean II gel apparatus Bio Rad 
Packard TopCountTM (harvester and 
microplate scintillation counter) 
Packard 
Parafilm M Kebolab 
Platform shaker (S25) Edmund Blücker 
Polyetylene (PE) Vials (6ml) with caps Packard 
Polystyrene Round-Bottom tube (5ml) Falcon 
Rotator mixer Stuart scientific 
Semicro disposable cuvettes (1,5ml) Plastibrand 
Sephadex G-50 NICK® Columns Pharmacia Biotech 
Spectrophotometer, Ultrospec 3000 Pharmacia Biotech 
Sterile scissors Rocket Medical 
Syringes (1, 2 or 5ml) Terumo 
TC-Plate, 96 well, U-shape Greiner 
Thin Layer Chromatography plate Merck 
TopCountTM Packard 
Trans-Blot® SD Semi-Dry Transfer Cell Bio Rad 
Ultrospec 3100 pro spechtrophotometer Amersham Biosciences 
Unifilter®-96, GF/C® PerkinElmer 
UV transilluminator Saveen 
Vortexer Heidolph 
Water bath Julabo 
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3.2 Isolation and culturing of normal T-lymphocytes 
 
3.2.1 Isolation of PBMC 
Peripheral blood mononuclear cells (PBMC) were separated from buffy coats of human 
blood donors, admitted to the Blood Bank at the Ullevål University Hospital in Oslo. A 
buffy coat contains lymphocytes, some platelets and monocytes, and is obtained by 
removing erytrocytes and plasma from full blood of normal donors. PBMC were isolated 
by use of Ficoll-Hypaque density gradient centrifugation (Boyum, 1968). The separation-
medium containing sodium-metrizoat and polysaccharide has a greater density than 
lymphocytes, so that these lymphocytes will be gathered on top of the reagent after 
centrifugation. Erythrocytes and granulocytes have an even greater density and will form 
a pellet in the bottom of the tube (see figure 11). It is inevitable that some platelets are 
isolated together with the lymphocytes, but the majority of these are removed by repeated 
washing and centrifugation. The desired T-cells will then be isolated by positive selection 
using magnetic beads coated with antibodies against CD4 (Miltenyi Biotec, Bergisch 
Gladbach, Germany), as described by the manufacturer. This procedure gives a great 
yield of T-lymphocytes, but the disadvantage is the high cost of magnetic beads. 
 
 
Equipment                                                                           Reagents and solutions      
Tissue culture flasks 250 cm2                                                  Buffy coat                                                                                          
Sterile scissors                                                                       Magnetic CD4 microBeads 
Plastic tubes 15 ml                                                                 RPMI/PS/Gln 
Plastic tubes 50 ml                                                                 RPMI/ 0.01M EDTA                                                      
Magnet adjusted to tissue culture flasks                                Carbonyl iron 70mg/ml 
Centrifuge                                                                              10% FBS 
Incubator                                                                                Ethanol 70%                                                                                             
                                                                                               Lymphoprep 
 
Fetal bovine serum (FBS) 
Before FBS is added to the RPMI 1640-medium, the serum has to be heated at 56ºC in at least 30 minutes 
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RPMI 1640 with penicillin, streptomycin and extra glutamine: 
RPMI 1640 – medium                                                500 ml 
Penicillin 5000 IE/ml-Streptomycin (PS) 5mg/ml        5 ml 
Glutamine  2mM                                                            5 ml 
 
The medium is kept in the refrigerator at 4ºC. 
 
Buffer for isolation of CD4+ T cells: 
FBS (0.5% (v/v))                                           500µl 
EDTA (stock: 0.5M) 2mM                            320µl                                                     





The isolation of PBMC is carried out aseptically in a workstation with vertical airflow, 
and use of a lab-coat and gloves is necessary to protect the individual performing the 
procedure in case the blood is infected. 
 
Six tubes each with 15 ml Lymphoprep are prepared beforehand. The buffy coat tube is 
sterilized with 70% ethanol, and a sterilized scissors is used to cut the tube off. The buffy 
coat is pored into a culture flask containing 160 ml cold RPMI/ 0.01 % EDTA. 35 ml of 
this mixture is carefully layered on top of the Lymphoprep in each of the six tubes. The 
tubes are centrifuged at 600 x g (with minimum brake) at room temperature for 20 
minutes. The red blood cells will now occur at the bottom of the tube, while a white layer 
of mononuclear cells (MNC: lymphocytes, macrofages and monocytes) appears on top of 







Figure 11. Before and after density gradient sentrifugation. 
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The mono nuclear cells from the six tubes are gently collected and placed on ice, before 
centrifugation at 500 x g for 10 minutes. About 3 ml of the supernatant is removed from 
each tube, and thereafter the tubes are rotated carefully to separate the platelets from the 
MNC-pellet. The remaining supernatant containing platelets is removed, and after 
resuspending the MNC-pellet in 7 ml RPMI, the cells are recollected in a 50 ml tube prior 
to centrifugation at 500 x g for 10 minutes. 
 
The supernatant is removed, and the pellet is resuspended in 10 ml RPMI/10% FBS.  
1 ml carbonyl iron with ethanol per 400 million cells is added to a 14 ml tube. The tube is 
placed on a magnet, the ethanol is removed and the carbonyl iron is washed twice with 
RPMI (5ml) and once with RPMI/10% FBS (5ml), before the carbonyl iron is 
resuspended in 5ml RPMI/10% FBS and placed in a culture flask. Cells and 
RPMI/10%FBS is added to a final cell concentration of 1.0 x 107 cells/ml. After 
incubating at 37 ºC for 45 minutes, the culture flask is placed on a magnet and the 
supernatant is transferred to a 50 ml tube on ice. The macrophages have now engulfed the 
carbonyl particles and are removed. The lymphocytes are counted and collected by 
centrifugation at 500 x g for 10 minutes. 
 
Isolation of CD4+ T-cells 
The isolation of CD4+ T-cells is now performed by using magnetic CD4 beads, and it is 
done according to the manufacturer’s description with only minor changes. It is important 
to work fast and to keep the solutions cold to avoid capping of antibodies at the cell 
surface and nonspecific binding of antibodies to the cells. 
 
The cells are washed with 1-2 ml buffer/10 7 cells by centrifugation at 500 x g for 10 
minutes. The supernatant is removed and the cell pellet is resuspended in 80 µl  
buffer/10 7 cells. The magnetic CD4 beads are added to the cells (20 µl of the magnetic 
beads/10 7 cells) and the cells are placed at 4-8 º C for 15 minutes. After centrifugation at 
500 x g for 10 minutes, the supernatant is removed and the cells are resuspended in 500 
µl buffer/108 cells. 
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The cells are now transferred to a LS (MACS) column that is placed on a magnet. All the 
cells that are bound to CD4 beads (CD4+ T cells) will remain in the column. CD4- cells 
will pass through the column and are removed. The column is washed with 3 ml buffer.  
The column is removed from the magnet, placed on top of a suitable collecting tube, and 
thereafter the CD4+ cells are flushed out by using the stamp. The cells are washed in 9 ml 
RPMI and collected by centrifugation at 500 x g for 10 min.  The cell pellet is 




3.2.2 Culturing normal T-cells 
When keeping cells in culture, it is essential to use aseptic technique to avoid 
contamination of microorganisms. As an extra precaution, the cell culture medium is 
often supplemented with antibiotics, penicillin and streptomycin (PS), to prevent growth 
of bacteria. The cells are grown in an incubator at 37ºC, with 5 % CO2 and humidified air 
to simulate an in vivo situation. When taken out of the incubator the cells must 
immediately be placed in a sterile cell culture hood. Gloves should be worn, and all 
equipment used should be sterile or washed with ethanol before brought into the hood. 
 
Normal T cells are grown in RPMI-medium. This medium contains inorganic salts, 
nutrients as amino acids and vitamins, glucose as an energy source, gluthatione and pH-
indicator. Glutathione (glutathion S-transferase) is a phase II biotransformation enzyme, 
which protects against oxidative damage. Extra glutamine is also added. No serum is 




Microtiter plates with 96- and 24-wells 
Incubator 
Sterile pipettes  
 
 
T cells were cultured in standard 96-or 24-well flat bottomed microtiter plates, at a 
density of 1,5x 106 cells/ml in RPMI 1640 supplemented with extra glutamine and PS.  
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3.3Methods for measuring cell proliferation 
3.3.1 Cell counting 
The Coulter counter is an electronic cell counter based on the principle that the electrical 
resistance in an electrolyte solution will change when particles pass the current. As each 
cell passes through a small aperture it impedes the current and causes a measurable pulse. 
The number of pulses signals the number of particles. The procedure was performed 
according to the manual of the Coulter Microdiff-18 instrument, and cells would be 
counted at a range between 0,1x106 to 50x106. 
 
 
3.3.2 Measure of DNA-synthesis by 3H-thymidine uptake. 
Cells that are activated into S phase will usually proceed to mitosis and eventually 
divide. Thus, incorporation of radiolabeled nucleic acid precursors, such as thymidine, 
into DNA during S phase of the cell cycle, is a widely used method to measure cell 
proliferation. The cells are harvested onto a glass fiber filter, free nucleosides removed, 







Equipment                                                                                         Reagents and solutions 
Microtiter plate with 96 wells                                                             RPMI/PS/Gln                                                    
Packard FilterMate cell harvester                                                       [3H]-Thymidine 1000 mCi/ml 
Glass fiber filter (Unifilter -96 GF/C filters)                                       MicroScint cocktail (Packard)  





T-cells are placed in 96 well flat-bottomed microtiter plates, in a total volume of 200 µl. 
The cells are incubated from 1-3 days, depending on what experiments that are being 
done. To each well is added 50 µl [3H] - thymidine (20mCi) and the cells are incubated 
for another 16-18 hours. The cells are harvested onto a glass-fiber filter (Unifilter-96 
GF/C filters) by using a semiautomatic cell harvester, before registration of incorporated 
[3H] thymidine in a scintillation counter according to the instrument manual. All samples 
are grown in triplicates in order to get statistically valuable data. 
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3.3.3 Determination of cell cycle distribution 
The classical method for determining cell cycle distribution is to simultaneously measure 
incorporation of bromodeoxyuridine (BrdU), and DNA content by flow cytometric 
analysis. BrdU is incorporated into the DNA of S phase cells and detected by using 
FITC-conjugated antibodies against BrdU. Anti-BrdU antibodies only recognize BrdU in 
denatured DNA. Therefore, DNA must be denatured in situ by means of alkali, acid or 
heat. Increased BrdU-incorporation in S phase cells and a doubling of the DNA content in 
G2 phase cells enables a separation of cells in G1, S and G2 phases of the cell cycle. The 
analysis is done by the use of a fluorescence activated cell sorter (FACS). This equipment 
measures and analyses optical properties of single cells passing through a focused laser 
beam. When cells pass through the laser beam, they disrupt and scatter the laser light, 
which is detected as forward scattered (indicates cell size) and side scattered light 






Equipment                                                                              Reagents and solutions 
24-well cell culture plates                                                        RPMI/PS/Gln (see section 3.1.1) 
CO2-incubator                                                                           FITC-labeled BrdU 
Plastic tubes 15 ml                                                                    PBS 
Polystyrene round bottom tubes                                               70% ethanol 
Flow cytometer (FACSCaliber)                                                Pepsin-HCl solution                                             
                                                                                                   Sodium tetra borate pH 8.5 
 
                                                                                                   IFA (Immunofluorescence Assay)-buffer 
                                                                                                      
                                                                                                   IFA-Tween 
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Pepcin-HCl:                                                                 
Pepcin                  0.3mg                                                                  IFA-buffer: 
HCl 2M         to 1000 µl                                                                   NaN3                              1ml 
                                                                                                          FBS                            40 ml 
                                                                                                          HEPES buffer 10X     96ml 
                                                                                                         





IFA          199ml                                                                         Antibody-BrdU-solution:     
 
Tween         1ml                                                                          FITC-conjugated anti Brdu- antibody   10 µl                                     
                                                                                                    IFA                                                       112 µl 
 
PI/Ribonuclease A solution: 
PI (stock=1mg/ml) 20 µg/ml                   80µl                                   10x HEPES-buffer: 
                                                                                                
RNase A (stock=10mg/ml) 40 µg/ml     16µl                                   HEPES             95.2g 
PBS                                                     to 4 ml                                  NaCl              350.8g                 
                                                                                                          Destilled water to 4 l 





Cells (300 000-500 000 cells/sample) are incubated for a chosen period of time. BrdU 
(10µM) is added to cells about 2 hours before harvesting. The cells are then centrifuged at 
500 x g for 10 minutes. The pellet is resuspended in 100 µl cold PBS, and 4 ml 70 % ice 
cold Ethanol is added while vortexing the tubes. The tubes are kept at 20◦C for at least 18 
hours. Thereafter, the cells are centrifuged at 400 x g for 5 minutes and the pellet 
resuspended in 1 ml pepsin-HCl for 30 minutes. The acid is neutralized with 3 ml 0.1 M 
sodium tetraborate (pH 8.5) and the cells are then collected by centrifugation. The cells 
are washed in 2-3 ml IFA, and after centrifugation the cells are resuspended in 2-3 ml 
IFA-T and incubated for 5 minutes at room temperature. After centrifugation the pellet is 
resuspended in 500 µl Rnase/PI solution, and the cells are incubated for 10 minutes in the 
dark. The cell suspension is transferred to Polystyrene Round-Bottom Tubes through a 
mesh-film and analyzed in a flow-cytometer according to the manual of the instrument.  
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3.3.4 CFSE-staining 
The overall goal of CFSE-staining cells is to determine the number of cell divisions of a 
cell population. CFSE (fluorescent-5-(and 6-) carboxyfluorescein diacetate, succinimidyl 
ester) is a dye that accumulates inside cells and is diluted, when the cells divide. The 
succinimidyl moiety of CFSE which is highly reactive becomes covalently coupled to 
nucleophils (e.g. amino acids) forming long-lived fluorescent conjugates that cannot 
escape from the cell, and this label remains stably associated with the cell. Thus, CFSE-
labeled cells can be used to analyze cell division, since the dye is evenly distributed to the 
progenies resulting in the halving of the fluorescence intensity after each division (Rodel 
et al., 2005). 
 
 
Equipment                                                                     Reagents and solutions 
 
96-well U-bottom cell culture plate                                CFSE (10mM) 
Polystyrene round bottom tubes                                     DMSO                                           
Flow-cytometer (FACSCaliber)                                     PBS 
CO2-incubator                                                                 PBS/20% FBS 
Plastic tubes 50 ml, 15 ml                                               RPMI/PS/10%FBS  




All handling with CFSE has to be done under the protection from light. 
CFSE is dissolved in 90 µl DMSO to a stocksolution at10mM, and the CFSE-solution is 
kept at -20◦C. The cells, about 50-60 millions, are washed once in PBS/0.5% FBS and the 
pellet is resuspended in 4 ml PBS. The CFSE-solution is diluted 30x in DMSO, and 2 µl 
of this dilution is transferred to a 50 ml plastic tube. The 4 ml cell suspension is quickly 
transferred to this tube, and thoroughly resuspended. The cell-CFSE mixture is incubated 
in a water bath at 37◦C and 20 ml PBS/20%FBS is added prior to centrifugation at 500 x 
g for 10 minutes. This washing step is repeated once prior to incubation for 1-2 hours. 
After centrifugation, the cell pellet is washed with 14 ml RPMI/PS/Gln/0.5% FBS and 
centrifuged at 500 x g, before 1 ml of the same medium is added.  
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3.4 Methods for measuring cell death 
 
3.4.1 Scatterprofile. Measuring the distribution of viable and dead cells 
A fluorescence activated cell sorter (FACS) is a powerful method to study different 
features of cells. When individual cells held in a thin stream of fluid are passed through 
one (or more) laser beams, they cause light to scatter. The scattered light is detected as 
forward scattered and side scattered light. Forward scatter approximates cell size, while 
side scatter is an indicator of the cell`s granularity or complexity (Swat et al., 1991).  
 
Loss of volume and increase of density is a characteristic feature of apoptotic cells. This 
is a result of apoptotic cells shrinking and being more granular than viable cells. In 
addition, chromatin condensates, the nuclei fragmentize and apoptotic bodies are formed. 
Thus, by analyzing the scatter profiles, it is possible to separate cells into viable cells, 
apoptotic cells and necrotic cells, since necrotic cells will swell, and are therefore larger 
than viable cells.  
 
3.4.2 PI-staining of cells 
By staining cells with Propidium iodide (PI) it is possible to distinguish between dead 
and viable cells. PI is a dye which binds DNA and is taken up by necrotic and late 
apoptotic cells, while viable and early apoptotic cells exclude PI, because they have an 
intact nuclei membrane. PI-staining of the cells is detected as red fluorescence in a flow 
cytometer equipped by an argon-laser.  
 
 
Equipment                                                                    Reagents and solutions 
96 well U-bottom cell culture plate                                RPMI/PS/Gln 
Polystyrene round bottom tubes                                     Propidium iodide (15µg/ml)      




All handling of PI should be done under protection from light. 
PI (70 µl) transferred to polystyrene round bottom tubes, and 140 µl cell suspension  
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(0, 2 mill cells) is added. After careful resuspension, the cell mixture is placed in the dark 
at roomtemperature for 10 minutes, (if desired the cell-suspension can be placed in the 
refrigerator for 1-2 hours), before it is analyzed for red fluorescence by flow-cytometry 
(PI-staining). The method is usually combined with analyzing forward and side scatter.  
 
 
3.5 Western blot analysis 
 
Western blot analysis is a technique used to detect (identify and quantify) specific 
proteins in a complex mixture of proteins. The protein samples are solubilized with 
detergents and reducing agents, denatured by boiling and separated electrophoretically on 
a polyacrylamide gel. The proteins are transferred from the gel to a nitrocellulose 
membrane and hybridized with antibodies that react specifically with antigenic epitopes 
displayed by the target protein attached to the membrane. The methods are based on the 
procedures described by Maniatis, 1989 (Maniatis et al., 1989). 
 
The main steps in Western blot analysis are: 
 
1. Preparation of cell sample for electrophoresis 
2. Determination of protein concentration 
3. Separation of proteins by electrophoresis on polyacrylamid gels 
4. Transfer of proteins from SDS-PAGE gel to nitrocellulose membrane 
5. Staining of proteins immobilized on nitrocellulose membranes with Ponceau 
6. Blocking of non-specific binding sites for immunoglobulines  on the 
nitrocellulose membrane 
7. Incubation of the nitrocellulose membrane in primary antibody directed against 
the target protein 
8. Incubation in horseradish peroxidase conjugated antibody (secondary antibody) 
9. Application of detection reagents (ECL solution) 
10. Exposure to film 
 
 
3.5.1 Preparation of cell sample for electrophoresis 
The cells are harvested and the proteins are solubilized using an appropriate lyses buffer. 
To avoid that intracellular proteases digest the target protein, inhibitors of proteases are 
added in the lyses buffer. It is also necessary to keep the protein extracts on ice at all 
times to prevent protein degradation.  
   44 
 
Equipment                                                                            Reagents and solutions 
24 wells cell culture plate                                                      Lyses buffer (RIPA-buffer) 
Plastic tubes 1,5 ml                                                                PBS 
                                                                                               FBS (10%) 
 
RIPA-buffer: 
                                                                   25 ml 
NaF                          50mM                        2.5 ml (0.5M) 
Na2VO4                      1mM                        250 µl                   
β-glyserophosphate 10mM                        0.5 ml (1M) 
Tris HCl pH7.4        50mM                        1.25ml (1M)              
NaCl                       150mM                        1.5 ml (2,5M) 
NP-40                            1%                        250 µl (100%) 
SDS                             0.1%                       250 µl (10%)                                  
EDTA                     0.5 mM                         25 µl  (0.5M) 
PMSF                       0.2mM                         50 µl  (0,1M) 
Leupeptin              10 µg/ml                         25 µl (10mg/ml) 
Aprotinin                     0.5%                           5 µl to 1 ml 





T-cells are seeded at a concentration of 1.5x 106 cells/ml in 24 wells plates. After treating 
the cells with various activators and/or inhibitors at different time intervals (see the 
various figure legends), the cells are collected, 10% FBS is added to the cells, and the 
cells are centrifuged at 500 x g for 10 minutes at 4 º C. The cell pellet is resuspended in 1 
ml cold PBS/0.2 % FBS and  transferred to 1.5 ml plastic tubes prior to centrifugation at 
500 x g for 10 minutes at 4 º C.  The supernatant is removed and 45 µl RIPA buffer is 
added to each tube (5 µl aprotinin and 1 µl PMSF is added to 1 ml RIPA buffer). Each 
sample is then vortexed every 5 minutes for 30 minutes, before they are centrifuged at 
13793 x g for 20 minutes. Whole cells, nuclei and mitochondria - membranes that are not 
lysated will be collected in the bottom of the tubes. The supernatant is transferred to new 
1.5 ml plastic tubes, and the protein concentration is determined, before the samples are 
quickly frozen in liquid nitrogen and stored at -80 º C. 
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3.5.2 Determination of protein concentration 
The Bio-Rad protein assay is performed according to the method of Bradford (1976).The 
Bio-Rad Protein assay is a dye-binding assay where a color change occurs from a 
brownish to an intense blue color when the Coomassie brilliant blue G-250 in an acidic 
solution binds to protein. The absorbance maximum shifts from 465 nm to 595 nm, and 
the absorbance at 595 nm is detected by the spectrophotometer 
 
 
Equipment                                                                                                  Reagents and solutions 
Centrifuge                                                                                                    γ-globulin 1mg/ml (dissolved in  
Plastic tubes 1. 5 ml                                                                                     destilled water)                                
Spectrophotometer, Ultrospec 3100 pro (Amerskam Biosciences)             RIPA-buffer 





A Bio- Rad reagent is diluted 1:5 in water, and standards are prepared by adding 1 ml of 
this solution to each 1.5 ml tube. 2 parallels of standard samples of 5, 10, 15, 20, 25 or 30 
µg γ-globuline are prepared. The samples are prepared by adding 2.5 µl lysate to 1 ml of 
the diluted Bio-Rad reagent. The samples and standards are transferred to disposable 
cuvettes and the absorbance at 595 nm is measured according to the manual of the 
spectrophotometer. A standard curve is constructed (based on the mean of the measured 




Figure 12. A standard curve showing the correlation between absorbance (595nm) and 
amount of γ-globulin. 
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3.5.3 Separation of proteins by acrylamid gel electrophoresis 
 
In gel electrophoresis larger molecules are impeded relative to smaller ones as the 
molecules migrate through the gel. In polyacrylamid gel electrophoresis, gels are made 
from polymerization of acrylamid and N, N`-methylenebisacrylamid induced by free 
radicals. N, N, N`, N`-tetramethylenediamine (TEMED) is added to the gel mixture for 
stabilizing the free radicals. It is the addition of ammonium persulphate (APS) that 
generates free radicals. The physical properties of the gel and its pore size are controlled 
by the proportion of polyacrylamid in the gel and its degree of cross-linking. Typically 12 
% acrylamid gels are used for high molecular weight proteins (> 50kDa). The gels have a 
short “stacking gel”at the top, and a “running gel” below. In the stacking gel the proteins 
are concentrated into a narrow band, and in the running gel the proteins are separated.  
 
The proteins must be denatured in SDS for 5-10 minutes before loading them on the gel. 
This is accomplished by boiling the samples in SDS together with the reducing agent β- 
mercaptoethanol for 5-10 minutes. The denatured polypeptides bind to SDS and become 
negatively charged.  
 
Equipment and reagents                                                           
Bio Rad Mini Protean II gel apparatus                                             




Heating block                                   
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 Solutions/buffers                                                                                          
                                                                                                  
1.5 M Tris-HCl, pH 8.8:                                                          
Tris base                  54.45 g                                                        3x SDS sample buffer:          10ml      
Distilled water         150ml                                                          Tris-HCl pH 6.8 1.5M       1166µl  
pH adjusted to 8.8 with HCl                                                        SDS 10%                          5140 µl 
Distilled water to 300 ml                                                             Glycerol 80%                    2260 µl 
                                                                                                     β-mercaptoethanol              125 µl 
                                                                                                     Distilled water                   1184 µl 
 
                                                                                                     Bromophenol blue is added to obtain a                                        
                                                                                                      




0,5M Tris-HCl, pH 6.8: 
Tris base                  12.114 g                                                     10 x elecrophoresis buffer (pH 8.3): 
Distilled water   to 200 ml                                                          Tris base           30 g/l            150 g                                               
pH adjusted to 6.8 with HCl                                                        Glycine            144g/l            720 g 
                                                                                                     SDS                   10 g/l             50 g 
                                                                                                     Destilled water                      to 5 l 
 
10% SDS:                                                      
SDS                                 10 g                                                     10% APS: 
Distilled water          to 100 ml                                                   APS                     100 mg 




The manual from Bio Rad is used when the polyacrylamid gels are formulated and 
prepared. For identification of p21Cip-1, p27Kip and cyclin D we used a 12% separating gel, 
whereas a 10 % separating gel was used for identification of cyclin A and E. The samples 
are prepared by dissolving equal amounts of proteins (40-60 µg cell lysate) in 3x SDS 
sample buffer to a final concentration of 1 x SDS. The samples are boiled for 5-10 
minutes, centrifuged at 13000 x g for 1 minute and then loaded onto the gel. The gel is 
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3.5.4 Transfer of proteins from SDS polyacrylamid gel to nitrocellulose 
 
In these experiments a semi-dry transfer apparatus is used for the transfer of the proteins 
from the gel to the nitrocellulose membrane.  
 
Equipment                                                                                  
Hybond ECL Nitrocellulose membrane                                      
Whatman 3 MM paper                                                                  




Transfer buffer:              
39mM glycine          14.65g                                                         TBS/Tween (0.1 %) buffer: 
48mM Tris base         29.1g                                                           Tris base 24.2 g 
10 % SDS               18.75ml                                                          NaCl          80 g  
Methanol  100%     1000ml  
Water  to                         5 l                                                         Tris-base is dissolved in 5 liter destilled 
The solution is stored at 4ºC.                                                       water,  NaCl is added and then pH is   
                                                                                                      adjusted to 7.6 with concentrated  
                                                                                                      HCl. Tween 20 is added to a final  
                                                                                     concentration of 0.1%     
                                                                                                          
                                                            
                                                                                                    
Procedure 
The stacking gel is removed and the running gel is equilibrated in transfer buffer. One 
piece of nitrocellulose filter and six pieces of Whatman 3MM paper is cut at the exact 
size of the gel, and placed in transfer buffer. 3 pieces of Whatman paper is placed in the 
transfer cell and the filter is put on top of the papers. The gel is placed on top of the filter 
and finally the three last Whatman papers are put on top of the gel. To remove any air 
bobbles, a glass tube is rolled over the “sandwich”. The transfer is carried out at room 
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3.5.5 Staining of proteins immobilized on nitrocellulose membranes with Ponceau S 
 
Staining of proteins with Ponceau S is essential to provide visual proof that transfer of 
proteins from the gel to the nitrocellulose  filter has taken place, and in the same time as 
an extra control of  equal loading. Ponceau S is a rapid reversible protein stain, which is 
easily washed off during the further processing of the Western blot. 
 
 
Reagents and solutions                                                 Ponceau S: 
Ponceau S                                                                        Ponceau S     0.5 g     
TBS/Tween (See section 3.5.4)                                       Acetic acid      1 ml 
                                                                                         Distilled water to 100 ml 
 
                                                                                         Ponceau S is dissolved in 1 ml acetic acid. 
                                                                                         The volume is then adjusted to 100 ml with  
                                                                                         distilled water.  
 
Procedure 
The filter is incubated in a tray containing Ponceau S for about 5 minutes. The filter is 
then washed several times with distilled water, and eventually with TBS/Tween, in order 





3.5.6 Blocking of non-specific protein binding sites on the nitrocellulose membrane 
 
To reduce the background of nonspecific binding of irrelevant proteins, the nitrocellulose 





5% Nestle Molico nonfat dried milk in TBS/Tween (0.1%) buffer. 
 
TBS/Tween (0.1% buffer: 
See section 3.5.4.  




A 5 % blocking solution is made by mixing 50 ml of TBS-Tween solution with 2.5 g 
dried milk and transferred to a tray. The filter is incubated in the blocking solution for 
one hour under gentle agitation.  
 
 
3.5.7 Incubation of the nitrocellulose membrane with antibodies 
The blot is incubated with an unlabeled antibody (the primary antibody) specific to the 
protein of interest, in the presence of blocking solution. The blot is then washed, before it 
is incubated with the secondary antibody which is coupled to an enzyme, horseradish 
peroxidase. After further washing, the antigen-antibody complex is visualized by 
chemiluminescence and autoradiography. 
 
Reagents and solutions 
Rabbit polyclonal IgG against cyclin D3, cyclin D2, cyclin A, p21Cip-1 or p27Kip1 or mouse monoclonal IgG 
against human pRB or cyclin E. 
Nonfat dried milk 
Sodium azide (NaN3) 
TBS/Tween 





Primary antibody solution for cyclin D3, cyclin D2, cyclin A, p21Cip-1 or p27Kip1 and pRB: 
Primary antibody against cyclin D3, Cyclin D2, cyclin A, p21 Cip-1  , p27Kip1 or pRB     1µg/ml 
Nonfat dried milk                                                                                                              0.5 % (final conc.) 
Sodium azide                                                                                                                     0.1% (final conc.) 
TBS/Tween (0.1%) buffer to 7 ml. 
 
Secondary antibody solution for cyclin D3 , cyclin D2, cyclin A, cyclin E, p21Cip-1, p27Kip1 and pRB: 
Peroxidase  labeled goat anti-rabbit(against cyclin D3 , cyclin D2, cyclin A, p21Cip-1 or p27Kip1)  
or goat anti-mouse IgG (against cyclin E or pRB).                                                                     1:6000   
Nonfat dried milk                                                                                                                         2% (final c.) 
TBS/Tween (0.1%) to 5 ml                                                           
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Procedure 
The blot is incubated with the primary antibody solution for about 2 hours at room 
temperature or over night at 4º C under careful agitation. The blot is washed for 10-15 
minutes four times in TBS/Tween, before the blot is incubated with the secondary 
antibody solution for 1 hour at room temperature under gentle agitation. Finally, the blot 




3.5.8 Detection of proteins by chemiluminescence and autoradiography 
 
The ECL Plus Western blotting detection system produced by Amersham Pharmacia 
Biotech provides a method for the detection of immobilized antigens conjugated to 
horseradish peroxidase (HRP) labeled antibodies. The combination of HRP and peroxide 
catalyzes the oxidation of the Lumigen PS-3 acridian substrate which generates thousands 
of acridinum ester intermediates per minute. These intermediates react with peroxide 
under slight alkaline conditions to produce a sustained, high chemiluminescence with 





Equipment                                                                               ECL PlusTM Western blotting system: 
ECL PlusTM Western blotting detection system                        Reagent A                   





Detection of proteins by chemiluminescence is performed according to the 
manufacturer’s description. Reagents A and B are mixed in a ratio of 40:1. The blot is 
placed on a piece of Glad Pack and excess TBS/Tween is drained off. The mixture of A 
and B is pipetted on to the membrane and the membrane is incubated for 5 minutes at 
room temperature. Excess detection solution is drained off, and the membrane is laid in a 
plastic folder with the protein side up, and put in a film cassette. A sheet of Hyperfilm 
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MP is placed on top of the membrane in a dark room; the film is exposed for 5 seconds to 
5 minutes, and then developed.  
 
 
3.6 Northern analysis 
 
3.6.1 Isolation of total-RNA from T-cells 
RNA is easily degraded by intracellular Ribonucleases (RNase). When working with 
RNA, it is therefore extremely important to avoid contamination of RNases from any 
sources. Various precautions must be followed in order to create and maintain an RNase-
free environment. Good aseptic technique should be used when working with RNA, and 
the isolation procedure should be done as fast as possible. Gloves must be changed 
frequently, and tubes are kept closed whenever possible. Isolated RNA must be kept on 
ice.  
 
Equipment and reagents 
RNeasy Mini Kit  
Plastic tubes 1.5 ml 
20-gauge needles 









RNeasy Mini Kit includes:                                  
β-Mercaptoethanol                                                                           RLT-buffer                                                          
Buffer RLT                                                                                       β- Mercaptoethanol    10 µl              
Buffer RW1                                                                                      Rnasin                         5.2µl 
Buffer RPE                                                                                        RLT-buffer              to 1 ml                
RNase-free water 
RNeasy columns 
2 ml and 1.5 ml collection tubes 
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Procedure 
Total-RNA was isolated by the use of Qiagen RNeasy Mini kit. This technology takes the 
advantage of the selective binding properties of a silica-gel-based membrane, and 
combines it with the speed of microspin technology. Up to 100 µg of RNA longer than 
200 bases can bind to the RNeasy silica-gel membrane because of a specialized high-salt 
buffer system. First, biological samples are lysed and homogenized by a highly 
denaturing guanidine isothiocyanate (GITC)-containing buffer, which immediately 
inactivates RNases to insure isolation of intact RNA. To get appropriate binding 
conditions, ethanol is added. Thereafter the sample is applied to an RNeasy column 
where the total RNA binds to the membrane, and contaminants are washed away. Finally, 
RNA is eluted in 30µl, or more, of water.  
 
The maximum amount of starting material is 1.0 x 107, and the isolation of total-RNA 
was performed according to the manufacturer’s manual: 
The cells (10 x 106) are subjected to centrifugation at 500 x g for 5 minutes. 1 ml 
PBS/0.5% is added to the pellet, and the resuspended the cell-suspension is transferred to 
plastic tubes (1.5 ml). After centrifugation at 300 x g for 5 minutes, the supernatant is 
removed and the cells are resuspended in 600 µl RLT-buffer and homogenized by passing 
the lysate about 20 times through a 20-gauge needle fitted to a syringe. The RLT-buffer is 
a highly denaturing guanidine isothiocyanate (GITC)-containing buffer, which 
immediately inactivates RNases to insure isolation of intact RNA. One volume (350 µl) 
of 70% ethanol is added and mixed well by pipetting. Ethanol is added in order to get 
appropriate binding conditions. 700 µl of the sample is applied to an RNeasy column, 
where the total RNA binds to the membrane. The tube is closed, and centrifuged at 
≥8000g for 15 seconds. The flow through is discarded. 700 µl Buffer RW1 is applied to 
the column. The tube is closed, and after new centrifugation, the flow through is again 
discarded. The RNeasy column is transferred to a new 2 ml collection tube and 500 µl 
Buffer RPE is added. The tube is closed and again subjected to centrifugation. The flow 
through is discarded, another 500 µl Buffer RPE is added, but this time the tube is 
centrifuged for 2 minutes, to dry the silica-gel membrane. To elute, the column is 
transferred to a new 1.5 ml collection tube, and 30-35 µl RNase-free water is applied 
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directly onto the RNeasy silica-gel membrane. The tube is closed, and subjected to 
centrifugation for 1 minute at ≥ 8000 x g. The column is discarded, and the isolated RNA 
is stored at -80◦C.  
 
 
3.6.2 Electrophoresis of RNA in agarose gels 
RNA is fractionated by electrophoresis through a 1% agarose gel containing 
formaldehyde. Formaldehyd is a denaturant which prevents intrastrand base pairing, and 
makes the migration rate of a single-stranded RNA entirely dependent on its length. All 
handling with formaldehyde should be done in a chemical ventilation hood, due to its 
great toxicity. The RNA-bands are detected by incubation in a solution of ethidium 
bromide (EtBr). EtBr slips in between the stacked base pairs of RNA and makes RNA 
fluorescence under UV-light. After staining with ethidium bromide, only two bands are 





Agarose gel apparatus                                                 Reagents 
Microwave oven                                                         Total-RNA samples 
UV transilluminator                                                    DEPC-treated water 





10x Running buffer with MOPS (10xRB/MOPS): 
0.5M EDTA                                10ml 
1.5M Sodium acetate              16.66ml   
Sodium hydroxide                          2g 
DEPC-treated water to 490 ml. The solution is then autoclaved. 20.93 g MOPS (3-[N-morpholino] 
propanesulfonic acid) is added and the pH adjusted to 7.0. The solution is stored dark at 4º C. 
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Bromphenol blue solution: 
Glycerol 70%          1.45ml                                           Agarose (1%) with formaldehyde: 
10xRB/MOPS           200µl                                           Agarose                     0.8 g 
DEPC-treated water 350 µl                                           10xRB/MOPS             8 ml 
0.03% w/v bromphenol blue                                          Formaldehyd 37% 14.4 ml 
 
                                                                                        DEPC-treated water to 80 ml. 
 
3xsample buffer with ethidium bromide: 
Formamide (deionized) 800 µl 
10xRB/MOPS              160 µl 
Formaldehyd 37%       256 µl 
 
1 µl ethidium bromide (10mg/ml) is added before use. 
 
Procedure 
The procedure is based on the method described by Maniatis et al (1989). 
Agarose (1%) gel with formaldehyde is prepared as follows: Agarose is added to the 
DEPC-treated water, and the mixture is boiled in a microwave oven until the agarose 
dissolves. The solution is cooled to about 55ºC, and prewarmed 10x RB/MOPS and 
formaldehyde (55ºC) are thereafter mixed with the agarose solution. The gel solution is 
poured into the mold and the comb is set into place. After about 30 minutes at 4ºC, the 
gel is completely set. The gel is then mounted in the electrophoresis tank, and the comb is 
carefully removed. Enough volume of 10x RB/MOPS to cover the surface of the gel is 
thereafter added. The total RNA samples are prepared by adding 2.5 volumes of 3x 
sample buffer containing ethidium bromide. The solution is incubated in a 65ºC water 
bath for 10 minutes, before it is placed on ice for 5 minutes. After adding 10 µl cold 
bromphenol blue solution, the sample is loaded into the slots of the gel. The gel is run at 
95V for the appropriate time and then placed on the UV-transilluminator for visualization 
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3.6.3 Northern blotting 
Northern blotting ensures that the RNA in the gel is transferred on to a nylon membrane 
by upward capillary transfer. When the transfer is carried out at a neutral pH, the RNA 
does not become covalently fixed to the nylon membrane. To form covalently bonds 
between the RNA and the nylon membrane, the membrane is baked at 80ºC (or exposed 
to UV irridation at 254 nm) before hybridization. 
 
 
Equipment                                                  Reagents 
Whatman 3MM paper                                  DEPC treated water 
Parafilm M                                                    
HybondTM-N                                                   
Glass plates                                                  20xSSC: 
Test tube                                                      Sodium chloride      175.3g 
Paper towels                                                Sodium citrate            88.2g 
Container                                                     DEPC-treated water to 800 ml 
Weight 
Vacuum oven                                              pH is adjusted to 7.0 with 10M NaOH. 





The method is a slightly modified version of the procedure described by Maniatis et al 
(1989). A glass plate is placed on top of a container containing 20xSSC. 3 pieces of 
Whatman filter (wider and much longer than the gel) are cut and soaked in 20xSSC, 
before they are placed on top of the glass plate. It is of great importance that the ends of 
the filters are well covered with buffer. A test tube is rolled over the surface of the filter 
paper to remove all air pockets. The gel is then placed on top of the filters in an inverted 
position. One piece of nylon membrane (1mm larger than the gel in both dimensions) is 
soaked in DEPC-treated water for 2 minutes and then in 20xSSC for 5 minutes before it 
is placed on top of the gel. All air pockets between the gel and the membrane are 
excluded by carefully rolling a test tube over the surface. A stack of paper towels (10 cm 
   57 
 
high) is then placed on top of the filter. Finally, a glass plate is placed on top of the stack, 
and the stack weighed down with a weight (about 500 g). The transfer is run for 16-18 
hours. The RNA is covalently bound to the membrane by irridation at 254 nm for 1 
minute (or baked at 80 ºC).  
 
The 28 S and 18S RNA bands, which are visualized under UV light, are marked on the 
membrane by a pencil, and the membrane is baked between two pieces of Whatman filter 




Figur 13. Schematic illustration of the Northern blot transfer setup. 
 
The following part of the Northern blot analysis (labeling of probes, hybridization and 
autoradiography) was done by another person in the lab, since that meant working with 
radioactivity in a hot lab. I have not participated in a radioactivity course and could 
therefore not perform these experiments myself. 
 
3.6.4 Labeling a DNA probe by random primer method 
The Klenow fragment of E. coli DNA polymerase I is used to label probes by the random 
priming method. DNA fragment identical to the RNA of interest is used as a template. 
Random-sequence primers, 6-9 bases in length, are annealed to the DNA fragments and 
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incubated with the Klenow fragment and radiolabeled dNTPs. The primers are extended 
to generate double stranded DNA. To separate the radiolabeled probe from 
unincorporated dNTPs, the labeling reaction mixture is run through a Sephadex G-50 
NICK® column. The amount of incorporated radioactivity is then measured by a 
scintillation counter. 
 




α-32P dCTP (10mCi/ml) 
Sterile water 
0.5M EDTA 
Mega primer DNA labeling system 
Sephadex G-50 NICK® Columns 
Microcentrifuge tubes 
Opti-fluor®  
Polyethylene (PE) Vials (6ml) with caps 
LS 6500, Multi-purpose scintillation counter 
 
 
The Mega prime DNA labeling system includes: 
dATP, dCTP, dTTP and dGTP                                                     1xTE, pH7.5: 
Reaction buffer                                                                              1M Tris-HCl, pH7.4   1 ml (final c.10mM) 
Primer                                                                                            0.5M EDTA, pH8.0   0.2ml (final c. 1mM) 







30 ng DNA template, 5 µl primer solution and sterile water to a final volume of 26 µl are 
mixed. The mixture is placed on a heat block at 100ºC for 5 minutes (to denaturize the 
DNA) before centrifugation at 10000 x g for a few seconds. The following reagents are 
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thereafter added in the following order: 4µl dATP, 4µl dGTP, 4µldTTP, 5µl reaction 
buffer, 5µl α-32P dCTP and 2 µl Klenow-enzyme. The reaction mixture is mixed and then 
incubated in a 37ºC water bath for 15 minutes. The reaction is terminated by the addition 
of 2 µl 0.5M EDTA before the solution is placed on ice. To separate the radiolabeled 
probe from unincorporated dNTPs, the labeling reaction mixture is run through a 
Sephadex G-50 NICK® column. After equilibrating the column with 3 ml 1xTE, pH 7.5, 
the radio labeled probe is carefully applicated into the column. The solution is absorbed 
into the gel bed, and then 2 ml 1xTE, pH 7.5 is added to elute the purified sample. 
Microcentrifuge tubes are placed under the column for sample collection (3 drops in each 
microcentrifuge tube). 2 µl of each fraction is transferred to 3 ml Opti-fluor®, and the 
amount of incorporated radioactivity is then measured according to the manual of the LS 
6500 Multi-purpose scintillation counter. The two fractions of the highest radioactivity  




3.6.5 Hybridization and autoradiography 
To locate the RNA of interest, the RNA samples that have been transferred and fixed to a 
nylon membrane can be hybridized with a specific radiolabeled probe. After treating the 
membrane with blocking agents to suppress nonspecific absorption of the probe, the 
membrane is incubated under conditions that favor hybridization of the radiolabeled 
probe to the target RNA. The membrane is washed extensively (to remove nonspecific 
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Equipment and reagents and solutions 




HybaidTM Hybridization oven 
Heating block 
Plastic box 




50x Denhardt’s  solution: 
Ficoll                              5g 
Polyvinylpyrrolidone     5g 
BSA                               5g 
Sterile distilled water to 500 ml. 
20xSSC:    





20x Denhardt’s solution         4ml (final concentration: 5X) 
20xSSC                                  10ml (final conc. 5XSSC) 
1M Na-P, pH 6.5                      2ml (final conc. 50mM) 
10%SDS                                0.4ml (final conc.0,1%) 
100% Formamide                  20ml (final conc. 50%) 
5mg/ml Salmon DNA              2ml (final conc. 250µg/ml 
In DEPC treated water to     40 ml  




Two sheets of RNase free nylon gauze and the Northern blot are soaked in 2xSSC. The 
blot (sandwiched between nylon gauze) is thereafter placed in the hybridization cylinder 
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with the RNA side facing the inside of the tube. 20 ml of hybridization solution is boiled 
for 10 minutes and then cooled on ice. The hybridization solution is transferred to the 
hybridization cylinder, and the blot is prehybridized at 42ºC for 2 hours in a hybridization 
oven containing a rotating wheel. Another 20 ml of hybridization solution is boiled for 10 
minutes before cooled on ice. The radio labeled DNA probe is denaturized by placing the 
tube on a heating block at 100ºC for 5 minutes. After cooling down on ice, the probe is 
transferred to the newly prepared hybridization solution. The prehybridization solution is 
discarded before transferring the hybridization solution containing the radio labeled DNA 
probe into the hybridization cylinder. The blot is incubated over night at 42ºC in the 
hybridization oven. After hybridization, the blot is transferred to a plastic box on a 
platform shaker, and then washed 30 minutes with 2xSSC/0.1%SDS followed by 30 
minutes with 1xSSC/0.1%SDS (at room temperature). Further washing is necessary if the 
background, measured by a Geiger counter, is too high. The blot is carefully dried before 


























4.1 The effect of RA on T cell proliferation and its role in stimulating 
the cell cycle machinery 
 
4.1.1 RA enhances T cell proliferation induced by anti-CD3 antibodies and IL-2 
We wished to determine whether RA is able to modulate IL-2-induced mitogenic 
signaling in T-lymphocytes. Earlier studies in our lab group had reported that RA 
enhances TCR/CD3-initiated signaling by increasing IL-2 production, and thus stimulates 
the proliferation of isolated human T cells. In order to evade the contribution to T cell 
proliferation which was caused by RA-induced IL-2 production, we added IL-2 receptor-
saturating concentrations of recombinant IL-2 (4ng/ml) in combination with anti CD3 
(2,5µg/ml) antibodies (OKT3). The experiments were performed in the absence of fetal 
bovine serum (FBS). This was done to avoid retinol which is found in serum, and may be 
intracellularly metabolized to RA. Thus, retinol could potentially mask the effect of 
exogenously added RA, and thereby influence the experiments. 
 
As shown in figure 14, RA potently increases T cell proliferation measured by DNA 
synthesis. We performed a statistical analysis, paired t-test, by using the SPSS program 
from Windows, to compare the cpm-values of cells from ten different donors stimulated 
with OKT-3 and IL-2 in the absence or presence of RA. A p-value (p<0.01) indicates that 
the difference between two samples are statistical significant. As indicated in figure 14, 
the difference between samples treated with OI or OIR were statistical significant. 
 
 























Figure 14. Isolated CD4+ T lymphocytes from 10 different donors were either cultured in 
medium alone, or stimulated with OKT-3 and IL-2 in the absence or presence of RA (50nM), and 
after 48 hours they were pulsed with 3H-thymidine for 18 hours, as described in “Materials and 
methods”. Mean cpm-values of ten independent experiments ± SEM are shown (**P<0.01, paired 
samples t-test).  M represents cells cultured in medium alone. OI represent cells treated with 




4.1.2 RA potentiates T cell proliferation in a dose-dependent manner 
To investigate whether the effect of RA on T cell proliferation was dose-dependent, we 
measured the incorporation of 3H-thymidine into DNA after treatment with different 
concentrations of RA (see figure 15). As illustrated in figure 15, optimal uptake of 3H-
thymidine was achieved at 100 nM RA, and effects of RA were observed at 
concentrations of RA as low as 0.01 nM.  
 
























Figure 15.   RA potentiates OKT-3/IL-2 induced T cell proliferation in a dose-dependent 
manner. 
CD4+ T lymphocytes were treated with OKT3/IL-2 in the absence or presence of RA at 
concentrations of RA: 0.01-0.1-1-10-50-100nM. After 48 hours the cells were pulsed with 3H-
thymidine for 18 hours, as explained in “Materials and Methods”. Mean cpm-values ± standard 
deviations of triplicates from one representative experiment of three are shown. 
 
 
4.1.3 RA potentiates DNA synthesis in a time dependent manner 
We also wished to determine the kinetics of the RA-effect by measuring DNA-synthesis. 
As shown in figure 16, the effect was noteworthy at day 2, and RA potently increased 
DNA synthesis at day 3 and 4. Thus, RA enhances OKT-3/IL-2-mediated T cell-
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Figure 16.   RA potentiates DNA synthesis in a time dependent manner. 
Isolated CD4+ T lymphocytes were either cultured in medium alone (M), or stimulated with 
OKT-3 and IL-2 (OI) in the absence or presence (OIR) of RA (50nM). After 24, 48 and 72 hours, 
respectively, the cells were pulsed with 3H-thymidine for 18 hours, as described in “Materials and 
Methods”. Mean cpm-values ± standard deviation of triplicates from one representative 
experiment of three is shown.  
 
 
4.1.4 RA potentiates T cell proliferation in a time-dependent manner 
We next wished to confirm the time-dependent effect of RA that was demonstrated by 
measuring DNA-synthesis (see section 4.1.3.), by direct measuring cell division. To do 
so, we stained the cells with CFSE. CFSE is equally distributed between the two daughter 
cells after cell division, and thus divided cells express half of the fluorescence of 
undivided cells, and for each new cell division the fluorescence is further reduced. This 
can be detected by flow cytometric analysis. As illustrated in the dot blot from one 
representative experiment (figure 17), T cells cultured in medium alone did not undergo 
cell division. At day 3, however RA had induced one round of cell division in 14% of the 
T cells (figure 17). At day 4, a larger fraction of cells stimulated with OKT3 and IL-2, 
had divided once, and a comparable proportion of the cells had undergone two cell 
divisions in the presence of RA. Hence, 42% of RA-treated T cells had divided, 
compared to only 10% in the absence of RA. After 5 days, 52% of RA-treated cells had 
divided, and among these cells a considerable proportion had undergone three cell 
divisions, whereas only 21% of the cells had divided in the absence of RA. According to 
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these data it seems that RA stimulates both the initiation and progression of the T cell 


























Figure 17.  RA potentiates T cell division in a time dependent manner. 
T cells were stained with CFSE as described in Materials and Methods, and the cells were treated 
with OKT-3, IL-2 and RA (100nM) as indicated. The cells were analyzed for percentages of 
divided cells after three, four or five days, respectively. The gatings were set in order to 
accommodate for the loss of CFSE-fluorescence by dying cells. Percentages of divided cells are 
indicated. One representative experiment of eight is shown. 
 
 
4.1.5 Effect of RA on the cell cycle distribution of T cells 
The effect of RA on the cell cycle distribution of isolated T cells was investigated. The 
distribution of cells in the different phases of the cell cycle was addressed by a combined 
method of BrdU incorporation, which measures the fraction of cells in S phase, and 
staining of DNA by propidium iodide, which measures the DNA content of cells. The 
analysis was performed by the use of flow cytometry. In general, the percentages of the 
cells that have passed the G1-phase were limited at day 1. At day 3, still most of the cells 
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cultured in medium alone were in G1, whereas 0.1% of the cells had entered the S-phase 
(figure 18). In cells stimulated with OKT3 and IL-2, the percentage of cells in S-phase 
has increased to 3.14%, whereas RA enhanced this percentage of cells to 9.8% (figure 




























Figure 18.    Effect of RA on the cell cycle distribution of T cells. 
CD4+-cells were either cultured in medium alone, or stimulated with OKT-3 and IL-2 in the 
absence or presence of RA (50nM). After 24, 48 and 72 hours BrdU was added at a final 
concentration of 10µM about two hours prior to harvesting. The cell cycle distribution was 
determined by flowcytometric analysis after staining the cells with FITC-conjugated antibodies 
against BrdU in the presence of propidium iodide (PI)/Rnase-solution as described in Materials 
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4.1.6 Effect of RA on T cell viability 
We next wished to investigate whether RA also is affected by cell death in terms of 
apoptosis. By flow cytometry it is possible to discriminate between living cells and 
apoptotic cells. Thus, apoptotic cells are smaller than living cells, and are more granular. 


























                                              




























































Figure 19A. Effect of RA on T cell viability. 
CD4+-cells were either cultured in medium alone (M), or stimulated with OKT-3 and IL-2 (OI) in 
the absence or presence of RA (50nM). After 3, 4 and 5 days the percentage of dead cells was 
determined by PI-staining as described in “Materials and Methods”. Forward- and side-scatter 
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Figure 19B.   
CD4+ T lymphocytes from eight different blood donors were either cultured in medium alone 
(M), or stimulated with OKT-3 and IL-2 in the absence (OI) or presence (OIR) of RA (100nM). 
The cells were analyzed for cell death by flowcytometri after three, four and five days, 
respectively.  Mean percentages of dead cells ± SEMs are shown (*P<0.05, **P<0.01, paired 
samples t-test, n=8).  
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As shown in figure 19B, RA did not affect T cell viability at day 3, and caused only a 
minor, reduction in cell death at day 4 and 5. The minor effect of RA on apoptosis could 
therefore not explain the enhanced DNA synthesis shown in figure 1A. 
 
 
4.1.7 RA stimulates the cell cycle machinery in T cells 
One of the required steps for G1- to S - phase is the phosporylation of the pRB protein  
(Harbour and Dean, 2000a; Harbour and Dean, 2000b). Hyper-phosphorylated forms of 
pRB (ppRB) migrate slower in SDS-polyacrylamid gels, and can therefore be detected 
and distinguished from hypophosphorylated pRB (pRB). As shown in figure 20, pRB 
phosphorylation was strongly increased by RA. The effect of RA was first notable at day 
2, and at day 3 pRB was primarily observed in its hyper-phosphorylated forms in the 
presence of RA. Phosphorylation of pRB is carried out by CDKs, whose activities are 
positively or negatively regulated by cyclins (of types D, E and A in the G1-S-phase) and 
CKIs (e.g.p27Kip1 and p21Cip1), respectively. T cells express cyclin D2, D3, E and A 
(Ajchenbaum et al., 1993; Firpo et al., 1994; Yam et al., 2002).As illustrated in figure 20, 
the protein levels of all the cyclins were clearly increased when the cells were stimulated 
with OKT-3 and IL-2. Whereas cyclin D2 expression was unaffected by RA, cyclin D3 
levels was markedly enhanced by RA already at day 1, and at day 2 and 3 a strong up-
regulation was observed. Cyclin E levels were unaffected by RA, while the cyclin A 
levels were upregulated by RA at day 2 and 3. It has been proposed that a down 
regulation of p27 Kip1 is a major target of IL-2-induced signaling (Firpo et al., 1994; Kwon 
et al., 1997; Nourse et al., 1994). This agrees with the observation that p27 Kip1 levels, in a 
time dependent manner, were reduced by treatment of T cells with OKT-3 and IL-2 
(figure 20) A minor further reduction of p27 Kip1 in the presence of RA was noted at day 
2, and a more apparent, but still relatively modest effect was observed  at day 3 (figure 
20). The expression of p21 Cip1 was unaffected by RA. In conclusion, the most striking 
effect of RA on the cell cycle machinery was its early induction of cyclin D3, followed 
by induction of pRB-phosphorylation.  
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Figure 20.  Effect of RA on pRB phosporylation, and expression of cell cycle regulatory 
proteins 
Isolated CD4+ T lymphocytes were either cultured in medium alone (M), or stimulated with 
OKT-3 and IL-2 in the absence (OI) or presence (OIR) of RA (50nM). After 24, 48 and 72 hours, 
whole cell extracts were prepared, and Western blot analyses, using antibodies against the 
indicated proteins were performed as described in “Materials and Methods. Hypo- and hyper-
phosphorylated pRB proteins are indicated (pRB and ppRB, respectively). One representative 




4.2 Mechanisms involved in RA-mediated potentiation of  T cell 
proliferation 
 
4.2.1 RA induces the expression of cyclin D3 at the level of mRNA 
We next wished to investigate if the early induction of cyclin D3 induced by RA could be 
regulated at the mRNA level. Total RNA was isolated by the use of Qiagen RNeasy Mini 
kit, and analyzed by Northern blotting using 32P-labeled cyclin D3 probes, followed by 
autoradiography. The results shown in figure 21, demonstrate a strong upregulation of 
cyclin D3 RNA-level in the presence of RA, indicating that RA enhances the expression 
of cyclin D3 at the mRNA level.  
 









Figure 21. Effect of RA on cyclin D3 mRNA in CD4+ T lymphocytes. 
CD4+ T lymphocytes were either cultured in medium (M) alone or with OKT-3 and IL-2 in the 
absence (OI) or in the presence (OIR) of RA (50nM). After 36 hours, total RNA was isolated and 
Northern analyses, using a specific radiolabeled probe to locate the RNA of interest, were 
performed as described in “Materials and Methods”, and in collaboration with Nikolai Engedal. 
As a control of equal loading, the rRNA levels present in the samples are shown. One 




4.2.2 RA-mediated enhancement of T cell proliferation and cyclin D3 expression is 
dependent on IL-2-induced signaling 
By using IL-2 receptor-saturating concentrations of IL-2 we had ruled out the possibility 
that RA stimulated the cell cycle machinery and T cell proliferation by increasing IL-2 
production. Still, we could not exclude the possibility that RA mediated its effect by 
modulating TCR/CD3-, and not IL-2-induced signaling. To clarify which of these two 
signaling pathways that were affected by RA in our systems, we used a specific inhibitor 
of JAK, AG-490 (Kirken et al., 1999; Wang et al., 1999). To begin with we tested the 
effects of various concentrations of AG-490 on T cell proliferation induced by OKT-3 
and IL-2. AG-490 was able to inhibit T cell proliferation in a dose-dependent manner, 
both in the absence and presence of RA (figure 22A), and RA did not affect cell viability 
(data not shown). We observed that the potency of RA to enhance T cell proliferation was 
gradually diminished with increasing concentrations of AG-490 (Figure 22A).Hence, 
whereas RA caused a 4-fold increase in 3H-thymidine uptake in the absence of AG-490, 
only a 2.9-1.8-, and 1.2-fold increase were found in the presence of the JAK-inhibitor at 
the following concentrations: 2.5µM, 10µM and 25µM. These results indicate that RA-
induced T cell proliferation is dependent on JAK-mediated signaling from the IL-2R. 
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Figure 22A.  AG-490 inhibits T cell proliferation and cyclin D3 expression. 
CD4+ T lymphocytes were treated with various concentrations of AG-490 as indicated and either 
cultured in medium (M) alone, or stimulated with OKT-3 and IL-2 in the absence (OI) or 
presence (OIR) of RA (50nM). After 48 hours, cells were pulsed with 3H-thymidine for 18 hours, 
as described in “Materials and Methods”. Mean cpm-values ± standard deviations of triplicates 
from one representative experiment of three are shown.  
 
Next, we assessed the effect of JAK-inhibition on the expression of cyclin D3. 
Remarkably, as shown in figure 22B, the expression of cyclin D3 was almost totally 
abolished by AG490 in cells treated with OKT-3 and IL-2, both in the presence and 
absence of RA. This indicated that IL-2 induced signals are crucial for the induction of 
cyclin D3 expression. To confirm that AG-490 indeed had inhibited JAK-activity, we 
investigated the inhibitor’s effect on STAT3 tyrosine phosphorylation, which is known to 
be mediated by JAKs (Wang et al., 1999). As shown in figure 22B, OKT-3/IL-2 induced 
tyrosine phosphorylation of STAT3 was markedly inhibited by AG-490, both in the 
absence and presence of RA, indicating that AG-490 potently inhibited JAK-activity. 
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Figure 22B.    
CD4+ T lymphocytes were either cultured in medium alone (M), or stimulated with OKT-3 and 
IL-2 in the absence (OI) or presence (OIR) of RA (50nM), as well as in the absence or presence 
of AG-490 (20µM), as indicated. After 72 hours, whole cell extracts were prepared and Western 
blot analysis, using antibodies against the indicated proteins were performed as described in 
“Materials and Methods”. After immunoprobing with cyclin D3-or phospho-STAT3 specific 
antibodies, each membrane was stripped and re-probed with antibodies recognizing total ERK 
(tot-ERK) or total STAT3 (tot-STAT3) proteins, respectively, a control for equal loading. One 
reproduceable experiment of two is shown. The experiment was performed as described in 
Materials and Methods, and in collaboration with Nikolai Engedal. 
 
 
4.2.3 The potentiating effect of RA on T cell proliferation seems not to be regulated 
by the ERK/MAPK pathway and the PI3K pathway downstream for the IL2-
receptor 
 
Both the ERK/MAPK pathway and the PI3K pathway downstream for the IL-2R play a 
role in cell proliferation and gene transcription. The signal molecule ERK of the 
ERK/MAPK pathway can regulate targets in the nucleus such as the transcription factor 
c-Myc (Pearson et al., 2001). C-Myc is known to be one of the genes regulated by 
retinoic acid (Balmer and Blomhoff, 2002). In the PI3K pathway, the protein- 
serine/threonine kinase Akt plays an important role in regulation of GSK-3, which 
regulates for instance D-type cyclins.  
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In order to investigate whether the ERK/MAPK pathway and/or the PI3K pathway, 
downstream for the IL-2 receptor are involved in the effect of RA on T cell proliferation, 
we used specific inhibitors. Thus we employed UO126, a specific blocker of the MAPK 
cascade by suppressing the activation of MAPK kinase (MKK1), and wortmannin, which 
inhibits PI3-kinase (Davies et al., 2000).  
 
We first assessed the effect of wortmannin (0, 5µM) on DNA-synthesis. Wortmannin 
generally inhibited DNA synthesis induced by OKT3 and IL-2 (figure 23). When 
wortmannin was added after 24 hours, thus allowing the OKT3/IL-2 mediated signaling 
to occur; the effect of RA was not abolished (figure 23). These data indicate that RA-
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Figure 23. Wortmannin is not able to abolish the effect of RA on T cell proliferation. 
CD4+ T lymphocytes were either cultured in medium alone (M), or stimulated with OKT-3 and 
IL-2 in the absence (OI) or presence (OIR) of RA (50nM) or Wortmannin (0.5 µM). After 48 
hours, cells were pulsed with 3H-thymidine for 18 hours, as described in “Materials and 
Methods”. Mean cpm-values ± standard deviations of triplicates from one representative 
experiment of three are shown.   
 
 
We then investigated the effect of the MAPK inhibitor UO126 (10 µM) on DNA 
synthesis induced by OKT-3 and IL-2. As shown in figure 24 we observed that this 
inhibitor could not abolish RA’s potentiating effect on T cell proliferation. When UO126 
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was added at time 0, it also inhibited the DNA synthesis induced by OKT3 and IL-2. 
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Figure 24. UO126 is not able to abolish the effect of RA on T cell proliferation. 
CD4+ T lymphocytes were either cultured in medium alone (M), or stimulated with OKT-3 and 
IL-2 in the absence (OI) or presence (OIR) of RA (50nM) or UO126 (10 µM). After 48 hours, 
cells were pulsed with 3H-thymidine for 18 hours, as described in “Materials and Methods”. 
Mean cpm-values ± standard deviations of triplicates from one representative experiment of three 
are shown.   
 
We also wished to assess the effect of PI3K- and MEKK1- inhibitors on the expression of 
cyclin D3. As shown in figure 25, OKT-3/IL-2-induced cyclin D3 expression was not 
abolished by wortmannin or UO126 in the presence of RA, which again indicates that 
neither the PI3K-pathway, nor the MAPK family pathway are involved in RA-stimulated 
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Figure 25.  The effect of Wortmannin and UO126 on cyclin D3 expression. 
CD4+T lymphocytes were either cultured in medium (M) alone, or stimulated with OKT-3 and 
IL-2 (OI) in the absence or presence (OIR) of RA (50nM). Wortmannin (0,5µM) or UO126 
(10µM) were added about 10 hours after the start of the experiment. After 44 hours whole cell 
extracts were prepared and Western blot analysis, using antibodies against cyclin D3 were 
performed, as described in “Materials and Methods”. One experiment of two is shown. 
 
 
4.2.5 RA-mediated enhancement of T cell proliferation involves RAR 
atRA is generally believed to mediate its cellular effects through binding to RAR and 
thereby regulate the transcriptional activity of target genes. Whereas atRA only binds to 
RAR, 9cisRA (9cRA) has high affinity to both RAR and RXR (Gronemeyer and 
Miturski, 2001). Previous work in our lab has shown that 9cRA and a specific RAR 
agonist, TTNBP, both increased IL-2 production to the same extent as did atRA in 
primary T lymphocytes stimulated with TPA (Ertesvag et al., 2002). As shown in figure 
26, 9cRA, as well as the RAR-agonists TTNPB and AM-580, mimicked the effect atRA 
on increasing T cell proliferation. Interestingly, also the RXR-agonists, SR11217 (SR) 
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Figure 26. The effect of various RAR-and RXR-agonists on DNA synthesis.  
CD4+ T lymphocytes were either cultured in medium alone (M) or stimulated with OKT-3 and 
IL-2 in the absence (OI) or presence of various RAR- and -RXR agonists at a final concentration 
of 100nM for all the agonists. OIR= OI+RA, OI/TT=OI+TTNPB, OI/Am=OI+Am580; 
OI/SR=OI+SR11217 and OI/AGN=OI+AGN194204, which are RXR-agonists. OI9c=OI+ 9 cis-
RA. After 48 hours, cells were pulsed with 3H-thymidine for 18 hours, as described in “Materials 
and Methods”. Mean cpm-values of four independent experiments ± SEM are shown. 
 
 
To verify the involvement of the RAR pathway, we used the RAR-selective antagonist, 
Ro 41-5253 (Apfel et al., 1992; Keidel et al., 1994). As shown in figure 27, a complete 
inhibition was noted at a concentration of 250nM of Ro 41-5253. Taken together, these 
results suggest that the effects of RA on cell proliferation are mediated through retionid 
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Figure 27.  The effect of the RAR-antagonist Ro 41-5253 on DNA synthesis. 
T cells were either cultured in medium alone (Med), or stimulated with OKT-3 and IL-2 in the 
absence (OI) or presence of RA (0.5 nM) (OIR) and/or Ro 41-5253 (Ro) (250nM). After 48 hours 
the cells were pulsed with 3H-thymidine for 18 hours, as described in “Materials and Methods. 



















5.1 Methodological considerations 
5.1.1 Isolation of normal CD4+ T- lymphocytes 
We isolated CD4+ T-lymphocytes from buffy coats obtained from human blood donors by 
first using density gradient separation. This method separates peripheral blood 
lymphocytes (PBL) from erythrocytes and granulocytes. Thereafter we employed “CD4 
microbeads” to isolate quiescent CD4 + T-lymphocytes by positive selection. As 
described by the manufacturer, Miltenyi Biotec, microbeads-binding antibodies against 
CD4, are developed for the separation of human cells based on the expression of CD4 
antigen. CD4 is expressed on T helper cells, but also at a lower level on monocytes and 
dendritic cells. The positive selection method results in an extremely pure population of T 
cells with purity of at least 98 % resting, mature T cells. Less than 2% of the cells 
expressed CD8 (Cytotoxic T cells) or CD56 (NK cells), and the yield is satisfactory with 
about 150 million stained cells per buffy coat. The T cells are still quiescent after being 
isolated by positive CD4 selection. The advantage of using normal T lymphocytes is that 
these cells have normal physiology which is not always the case when working with 
malignant T cells, i.e. the human leukemia-derived T cell line Jurkat. This is an important 
aspect when the goal is elucidating mechanisms on how T cells work in combination with 
other agents in affecting the immune system.  However, the disadvantage of using normal 
T-cells is that the isolation is time-consuming and expensive. 
 
T cells can also be isolated by fluorescence activated cell sorting (FACS). The FACS- 
machine can separate the cells in a suspension on the basis of size and the color of their 
fluorescence. The cells of interest are labeled with specific monoclonal antibodies 
coupled to fluorescent dyes, and in case of T cell isolation one would use monoclonal 
antibodies against CD4. FACS is a good way of isolating lymphocytes based on their 
individual properties; however it is quite time consuming for isolation of large numbers 
of cells.  
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5.1.2 Activation of normal CD4+ T-cells 
In the body, T cells are activated by interaction between TCR and antigen displaced in 
the surface of antigen presenting cells. This, together with a second costimulatory signal, 
triggers a cascade of events that culminates in IL-2 production which drives the cell to 
proliferate. Activation of T lymphocytes in vitro can be mimicked by both synthetic and 
natural agents, such as anti-CD3 (OKT-3) and anti-CD28 antibodies, concanavalin A 
(Con A), phytohemagglutinin (PHA), and 12-O-tetradecaanoylphorbol 13-acetate (TPA) 
(Abb et al., 1979; Coligan et al., 1992). In our study we used the more physiological 
agent anti-CD3 antibody together with recombinant IL-2 (rIL-2) in order to activate the T 
cells. Anti-CD3, as its name imply, binds to CD3 which in the membrane of T cells is 
linked to TCR, and triggers the TCR/CD3 signaling events. RIL-2 binds to its IL-2 
receptor and induces down-stream signaling resembling the in vivo process. 
  
Others in our lab have used TPA or conA to stimulate T cells (Ertesvag et al., 2002). The 
tumor-promoting phorbol ester TPA activates T cells by mimicking diacylglyserol in 
activation of PKC (Nishizuka, 1984), and thereby bypasses the need for Ag-binding 
(Isakov and Altman, 1987). ConA, a mitogenic plant lectin, stimulates 20% or more of 
the T lymphocyte population (Kilpatrick, 1999). ConA binds to carbohydrate moieties of 
the T-cell receptor (TCR)-CD3 complex and co-stimulatory receptors, which is believed 
to induce a TCR- and co-stimulatory form of T-cell activation (Diehn et al., 2002). The 
stimulation of T cells with anti CD3/IL-2 is, however, considered to be a more 
“physiological” way of stimulating the cells.  
 
 
5.2 Discussion of the results 
5.2.1 The effect of RA on T cell proliferation and its role in stimulating the cell cycle 
machinery 
Earlier studies in our lab had reported that RA enhances TCR/CD3-initiated signaling by 
increasing IL-2 production through a mechanism that involves RAR, and thus stimulates 
the proliferation of isolated human T cells (Ertesvag et al., 2002). Our goal now was to 
determine whether RA is able to modulate IL-2 induced signaling in T-lymphocytes. To 
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exclude the interference from RA inducing IL-2, we used saturatory concentrations of IL-
2 in all the experiments. We could demonstrate that physiological concentrations of all-
trans retinoic acid potently enhance DNA synthesis and the proliferation of freshly 
isolated human T lymphocytes that were simultaneously stimulated with anti-CD3 
antibodies and saturating concentrations of IL-2. 
 
i) The effect of serum on RA-mediated stimulation of T cells 
In the present study, we have performed the experiments in the absence of fetal bovine 
serum (FBS). This was done in order to avoid retinol, which is found in serum (Fuchs and 
Green, 1981; Ishida et al., 2003). The serum we use has also been analyzed for the 
content of RA by the group of Rune Blomhoff, Department of Nutrition, and it was found 
that it contained approximately 0.6 µM retinol (data not shown). Experiments done by 
post doc Nikolai Engedal in our lab showed that the potentiating effect of RA on T cell 
proliferation was mostly abrogated in the presence of FBS. One explanation for this could 
be that some of the retinol which may be present in serum (Fuchs and Green, 1981; Ishida 
et al., 2003) is metabolized to RA by the T cells, thus providing enough RA to stimulate 
T cell proliferation in our experimental conditions. Another explanation of why serum 
diminished the effect of RA on T cell proliferation, could be that it contains factors 
(others than retinol) that may replace/ or inhibit the effect of RA. It has been shown that 
serum in fact contains factors that may stimulate (Clevenger et al., 1990) or inhibit, 
(Kucharz and Goodwin, 1988) IL-2 induced proliferation of T cells.   
 
 
Culturing cells in the absence of serum can indeed be argued as being “physiological”, 
and also other groups have omitted serum from the culture medium (Allende et al., 1997; 
Friedman et al., 1993; Garbe et al., 1992). Naive lymphocytes are known to wander 
through the blood and the lymph to the secondary lymphoid organs, whereas the activated 
T cells may wander out to the infected tissue where they participate in the local “war” 
against the pathogen. The activation of T cells takes place in lymph nodes, spleen, Paye’s 
patches in the small intestine, in adenoid glands and the tonsils in the human body. In 
lymph nodes is probably the availability of growth factors from the blood restricted, due 
   83 
 
to limited blood supply, and only low molecular substances are able to pass through. 
However, the blood flows right through the spleen, and therefore will the spleen be more 
exposed to growth factors. Thus, the amount of serum-derived growth factors available 
for T cells throughout the body may vary, and it is therefore important to examine the 
effect of RA also under limited inference from serum. 
 
ii) RA affects IL-2 signaling per se and not TCR/CD3 signaling 
We suggest that the stimulatory effect of RA on T cell proliferation under the present 
conditions is due to enhanced IL-2 mediated signaling, and not enhanced TCR/CD3-
signaling. First, by using IL-2 receptor-saturated concentrations of IL-2, we ruled out a 
possible contribution from RA-mediated stimulation of IL-2 production. Second, in the 
presence of the JAK-inhibitor AG-490, which blocks IL-2 induced signaling, the 
observed increased T cell proliferation, was abolished. In addition, experiments 
performed by post doc Nikolai Engedal in our lab, revealed that the TCR/CD3-induced 
signaling was not blocked by the JAK-inhibitor, AG-490. TCR/CD3-induced signaling 
leads to a rapid upregulation of IL2R-α (CD25) on T cell surface, and he observed that 
the early induction of IL-2R-α was not affected by RA (data not shown). Our finding that 
RA may stimulate T cell proliferation by affecting IL-2 mediated signaling is supported 
by other studies. Sidell and coworkers studied IL-2-maintained lymphoblasts generated 
from human thymocytes (Sidell et al., 1993), whereas another research group studied the 
effect of RA on a murine IL-2-dependent T cell line, HT-2 (Jiang et al., 1992). Our group 
is however, the first to study normal human T lymphocytes, and we are also the first to 
study physiological activators like anti CD3, and to simultaneously stimulate the cells 
with anti CD3 and RA. This is relevant, since it has been shown that both IL-2 and IL-2R 
are expressed early in the activation of T cells (Lea, 2000). 
 
 
iii) The effect of RA on the cell cycle machinery 
IL-2 initiates T cell proliferation by promoting G1- to S-phase cell cycle transition 
(Nelson and Willerford, 1998). Thus, we wanted to investigate potential effects of RA on 
the important components of the cell cycle machinery which regulate the G1-to S-phase 
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transition in T cells. In accordance with the increased effect of RA on DNA-synthesis 
notable at day 3, we observed that the phosphorylation of pRB was strongly enhanced at 
day 2 and 3. Amongst the G1-cyclins, the earliest and most pronounced effect of RA was 
the induction of the cyclin D3 expression notable already at day 1. Cyclin D3 can 
contribute to succession through the cell cycle in two ways. First, cyclin D3 can activate 
CDK4 and CDK6 directly, and then this complex enters the nucleus and phosporylates 
the Rb-protein. Second, cyclin D3 can indirectly activate CDK2 through binding to 
CDK4 and CDK6, thus titrating the CKIs p21Cip1 and p27Kip1 away from the cyclin 
E/CDK2 complex, which further accelerates the cell cycle progression (Coqueret, 2002; 
McGowan, 2003). It has been reported that downregulation of p27Kip1 expression is 
essential for IL-2-mediated CDK2-activation, and thus for G1-to S-phase in both human 
and murine T-cells (Firpo et al., 1994; Mohapatra et al., 2001; Nourse et al., 1994). In 
fact, we observed that RA moderately reduced the p27 Kip1 protein levels, but only at day 
2 and day 3, and could therefore be a result, rather than the cause of G1- to S-phase 
transition. RA did not alter the p21Cip1 protein levels, and we also observed that neither 
the expression of cyclin D2, nor cyclin E was affected by RA. Therefore, we suppose that 
RA allows CDK2 activation and pRb hyperphosphorylation predominantly by cyclin D3-
CDK4/6 complex-mediated sequestration of p21Cip1 and p27 Kip1.  Furthermore, the cyclin 
A level was upregulated by RA. An interesting feature of cyclin A is that there are both 
an embryonic and a somatic form of the protein. Humans for instance have two A-type 
cylins, an embryonic specific cyclin A1 and a somatic cyclin A2. Cyclin A1 is only 
expressed in meiosis and very early embryos, whereas cyclin A2 is present in 
proliferating somatic cells (Yam et al., 2002).It is known that E2F is inhibited by binding 
to hypophosphorylated pRb family proteins during G1, but their phosphorylation by 
cyclin D/E-CDK complexes releases E2F, which is then able to activate the transcription 
of genes involved in S phase progression (including that of cyclin A). In addition, cyclins 
in G1 can stimulate the transcription of cyclin A (A2) in S phase (Yam et al., 2002). 
Thus, since cyclin A gene transcription is believed to be a downstream target of both 
cyclin D (Schulze et al., 1996)and pRb (Knudsen et al., 1999), the observed upregulation 
of cyclin A could as well be a direct consequence of RA-mediated enhancement of pRb- 
phosphorylation and increased cyclin D3 expression.  
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Previous studies have indicated that cyclin D2 (Lea et al., 2003), cyclin A and cyclin E 
(Firpo et al., 1994; Mohapatra et al., 2001)is mostly induced by TCR/CD3 signals, and 
only slightly induced by IL-2 initiated signals, whereas cyclin D3 expression (Lea et al., 
2003; Modiano et al., 1995) seems to be primarily induced by IL-2 signaling. This is in 
agreement with our finding that cyclin D3 expression was almost fully abolished when 
IL-2 signaling was blocked by AG-490, both in the presence and absence of RA.  
 
 
5.2.2 Mechanisms involved in RA-mediated potentiation of T cell proliferation 
As cyclin D3 was the main cyclin affected by RA, observed by its early induction, we 
therefore focused on this protein. Cyclin D3 can be regulated at various levels. These 
include regulation of the transcriptional level of the gene (Wang et al., 1999), mRNA 
stability (Garcia-Gras et al., 2000), mRNA translation (Gutzkow et al., 2003) and cyclin 
D3 protein stability (Naderi et al., 2004). We observed that RA led to a very similar 
increase of both cyclin D3 protein and mRNA levels, indicating that the RA-enhanced 
expression of cyclin D3 was induced at the mRNA-level. Since, to our knowledge, there 
does not exist any RAR-responsive elements in the cyclin D3 promoter, we suppose that 
the effect of RA on cyclin D3 mRNA expression is indirect, but this remains to be 
elucidated. 
 
In attempt to elucidate mechanisms involved in RA-mediated potentiation of T cell 
proliferation, we investigated if any of the known signaling pathways downstream for IL-
2R are involved. JAK-mediated tyrosine phosphorylation of STAT5 is a proximal IL-2 
induced signaling event which is involved in IL-2-mediated T - cell proliferation, and 
STAT3 requires both tyrosine and serine phosphorylation for full activation (Benczik and 
Gaffen, 2004; Ellery and Nicholls, 2002; Gesbert et al., 1998). Experiments performed by 
Nikolai Engedal showed that neither STAT-5 nor STAT-3 phosphorylation were 
enhanced by RA, but that their phosphorylation were both increased after 1 day of 
OKT3/IL-2-treatment (data not shown). STAT-5- phosphorylation was observed as early 
as 15 min after treatment with OKT-3 and IL-2 (data not shown). This suggests that 
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proximal IL-2 signaling is not dependent of STAT-5 or STAT-3 phosphorylation in our 
system. It has been demonstrated that the activation of STAT molecules does not appear 
to be essential for cellular proliferation (Ellery and Nicholls, 2002). 
 
IL-2 R-ligation activates the PI3K/Akt-pathway and the MAPK/ERK pathway, which 
both are known to upregulate the expression of D-type cyclins (Ellery and Nicholls, 
2002; Moon and Nelson, 2001; Sears and Nevins, 2002). We therefore investigated if 
these two pathways could be involved in the early upregulation of cyclin D3 expression 
caused by RA. However, by using wortmannin (a PI3K-inhibitor) and UO126 (a MKK1- 
inhibitor) we could exclude the involvement of these pathways. In addition we observed 
that none of these inhibitors could abolish the ability of RA to stimulate OKT-3/IL-2-
induced DNA-synthesis. In support of this conclusion, Nikolai Engedal found that RA 
did not enhance cyclin D3 expression through Akt and ERK-stimulation. Nevertheless, he 
observed that OKT-3 and IL-2 induced a strong upregulation of both Akt and ERK which 
sustained for at least 22 hours (data not shown). Thus, from these data we have so far not 
been able to demonstrate that RA regulates a single, downstream IL-2-induced event, 
other than that it is dependent on JAK.  
 
It is well known that retinoic acid mediates its effect mainly through the RAR/RXR-
heterodimer, which binds to RA-response elements located in the promoter region of RA 
target genes (Balmer and Blomhoff, 2002; Despouy et al., 2003; Gronemeyer and 
Miturski, 2001). We wished to investigate if RA in our experiments did mediate its effect 
through RAR. In fact, we observed that two different RAR-agonists were able to mimic 
the effect of RA on T cell proliferation, and that a RAR-selective antagonist suppressed 
the effects of RA. Thus, it appears that RARs have a key role in mediating the effects of 
RA on transcriptional regulation. In previous studies done by our group, it was found that 
RA stimulated TCR/CDR initiated signals also through a mechanism involving RAR 
(Ertesvag et al., 2002). Interestingly, however, also the RXR-agonists, SR11217 (SR) and 
AGN194204 (AGN) were able to enhance OKT-3/IL-2 induced DNA synthesis. This is 
to our knowledge one of the very few studies having found any effect of RXR-agonists, 
and it could be due to some RA already being bound to RAR in the cells. This we suggest 
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in the light of previous studies where it has been reported that only RAR-, but not RXR-
ligation is sufficient to activate RAR/RXR heterodimer, and in addition simultaneously 
ligation of both RAR and RXR acts synergistically on RAR/RXR transcriptional activity 
(Bastien and Rochette-Egly, 2004; Gronemeyer and Miturski, 2001).  
 
As previously mentioned, we have not been able to demonstrate that RA regulates any of 
the known IL-2 signaling pathways downstream of the IL-2 receptor. However, it is 
likely that RA via the RAR/RXR acts further downstream, for example at the level of 
gene transcription, to change the expression of IL-2 responsive genes. Interestingly, 
experiments performed by post doc Nikolai Engedal, has recently shown that the protein 
expression of c-Myc, was upregulated within 5 hours after treating the cells with OKT-3 
and IL-2. C-Myc is a transcription factor important in cell proliferation (Sears and 
Nevins, 2002). Cyclin D3 has recently been shown to be transcriptionally upregulated by 
c-Myc (Yu et al., 2005), and IL-2 induces c-Myc expression through a JAK3-dependent 
pathway (Nelson and Willerford, 1998). Thus, the observed RA-mediated up-regulation 
of c-Myc could give a possible explanation for the observed, JAK-dependent induction of 





The overall purpose of this thesis has been to elucidate if RA is able to enhance IL-2 
mediated signaling in T cells, independent of its capacity to induce IL-2. 
 
We have the following specific conclusions: 
1. RA enhances IL-2 mediated proliferation in human T cells through a pathway 
dependent of JAK. 
2. RA stimulates the cell cycle machinery induced by OKT3 and IL-2, and the most 
prominent effect of RA is the early induction of cyclin D3, as well as a strong 
phosphorylation of pRB.  
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3. RA induces the expression of cyclin D3 both at the mRNA-level and protein 
level. We were not able to show that RA affects any of the most known signaling 
pathways downstream of the IL-2 receptor (the JAK/ STAT-, the MAPK/ERK-, 
and the PI3K-pathway). 
4. The effect of RA on IL-2 mediated signaling involves the nuclear receptor RARs 
and RXRs.  
 
Taken together, our results indicate that RA enhances IL-2 mediated proliferation by 
inducing the expression of cyclin D3 in a JAK-dependent manner, and that the effects of 




We observed that RA led to a strong upregulation of cyclin D3 at the mRNA-level, and it 
would therefore be interesting to determine if cyclin D3 is a result of induced 
transcription or by stabilization of mRNA. This can be established by performing real-
time PCR to measure the mRNA levels of cyclin D3, where the half life of cyclin D3 
mRNA indicate its stability. Nuclear run-on experiments can be performed to analyze the 
transcriptional induction of cyclin D3, and finally it is possible to measure the stability of 
cyclin D3 mRNA by treating the cells by the RNA polymerase II inhibitor, DRB (5, 6-
dichloro-1β-D-ribofuranosylbenzimidazole (Pallet et al., 2005). 
 
We were not able to demonstrate an effect of RA on any of the common signaling 
pathways downstream of the IL-2 receptor, including the JAK/STAT-, the MAPK/ERK- 
and the PI3K-pathway. Flores and coworkers have demonstrated that IL-2 signaling also 
is dependent on the DAGK-α pathway by inducing phosphatidic acid production (Flores 
et al., 1999; Sanjuan et al., 2003). In their experiments, they employed a specific inhibitor 
of DAGK-α, R59949. We will use this inhibitor to unravel a possible effect of RA on this 
pathway. 
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Finally, we would also like to establish whether the RA-mediated upregulation of c-Myc 
is the mechanism behind the observed early induction of cyclin D3 by RA, and this will 






































   90 
 
6. REFERENCE LIST 
 
 
Abb,J., Bayliss,G.J., and Deinhardt,F. (1979). Lymphocyte activation by the tumor-
promoting agent 12-O-tetradecanoylphorbol-13-acetate (TPA). J. Immunol. 122, 1639-
1642. 
Ajchenbaum,F., Ando,K., DeCaprio,J.A., and Griffin,J.D. (1993). Independent regulation 
of human D-type cyclin gene expression during G1 phase in primary human T 
lymphocytes. J. Biol. Chem. 268, 4113-4119. 
Aktas,H., Fluckiger,R., Acosta,J.A., Savage,J.M., Palakurthi,S.S., and Halperin,J.A. 
(1998). Depletion of intracellular Ca2+ stores, phosphorylation of eIF2alpha, and 
sustained inhibition of translation initiation mediate the anticancer effects of clotrimazole. 
Proc. Natl. Acad. Sci. U. S. A 95, 8280-8285. 
Alberts,B., Johnson,A., Lewis,J., Raff,M., Roberts,K., and Walter,P. (2002). Molecular 
Biology of The Cell. (New York: Garland Science, Taylor & Francis Group). 
Alberts,B., Bray,D., Lewis,J., Raff,M., Roberts,K., and Watson,J.D. (1994). Molecular 
Biology of The Cell. (New York: Garland Publishing, Inc.). 
Allende,L.M., Corell,A., Madrono,A., Gongora,R., Rodriguez-Gallego,C., Lopez-
Goyanes,A., Rosal,M., and Arnaiz-Villena,A. (1997). Retinol (vitamin A) is a cofactor in 
CD3-induced human T-lymphocyte activation. Immunology 90, 388-396. 
Apfel,C., Bauer,F., Crettaz,M., Forni,L., Kamber,M., Kaufmann,F., LeMotte,P., 
Pirson,W., and Klaus,M. (1992). A retinoic acid receptor alpha antagonist selectively 
counteracts retinoic acid effects. Proc. Natl. Acad. Sci. U. S. A 89, 7129-7133. 
Bahl,R., Bhandari,N., Kant,S., Molbak,K., Ostergaard,E., and Bhan,M.K. (2002). Effect 
of vitamin A administered at Expanded Program on Immunization contacts on antibody 
response to oral polio vaccine. Eur. J. Clin. Nutr. 56, 321-325. 
Bakiri,L., Lallemand,D., Bossy-Wetzel,E., and Yaniv,M. (2000). Cell cycle-dependent 
variations in c-Jun and JunB phosphorylation: a role in the control of cyclin D1 
expression. EMBO J. 19, 2056-2068. 
Balmer,J.E. and Blomhoff,R. (2002). Gene expression regulation by retinoic acid. J. 
Lipid Res. 43, 1773-1808. 
Bastien,J. and Rochette-Egly,C. (2004). Nuclear retinoid receptors and the transcription 
of retinoid-target genes. Gene 328, 1-16. 
Benczik,M. and Gaffen,S.L. (2004). The interleukin (IL)-2 family cytokines: survival and 
proliferation signaling pathways in T lymphocytes. Immunol. Invest 33, 109-142. 
   91 
 
Benn,C.S., Balde,A., George,E., Kidd,M., Whittle,H., Lisse,I.M., and Aaby,P. (2002). 
Effect of vitamin A supplementation on measles-specific antibody levels in Guinea-
Bissau. Lancet 359, 1313-1314. 
Blomhoff,H.K. and Smeland,E.B. (1994). Role of Retionids in Normal Hematopoiesis 
and the Immune System. In Vitamin A in Health and Disease, R.Blomhoff, ed. (New 
York: Marcel Dekker,Inc.), p. 451. 
Blomhoff,H.K., Smeland,E.B., Erikstein,B., Rasmussen,A.M., Skrede,B., Skjonsberg,C., 
and Blomhoff,R. (1992). Vitamin A is a key regulator for cell growth, cytokine 
production, and differentiation in normal B cells. J. Biol. Chem. 267, 23988-23992. 
Blomhoff,R., Green,M.H., Berg,T., and Norum,K.R. (1990). Transport and storage of 
vitamin A. Science 250, 399-404. 
Breckenridge,D.G. and Xue,D. (2004). Regulation of mitochondrial membrane 
permeabilization by BCL-2 family proteins and caspases. Curr. Opin. Cell Biol. 16, 647-
652. 
Chang,F., Steelman,L.S., Shelton,J.G., Lee,J.T., Navolanic,P.M., Blalock,W.L., 
Franklin,R., and McCubrey,J.A. (2003). Regulation of cell cycle progression and 
apoptosis by the Ras/Raf/MEK/ERK pathway (Review). Int. J Oncol. 22, 469-480. 
Clevenger,C.V., Russell,D.H., Appasamy,P.M., and Prystowsky,M.B. (1990). Regulation 
of interleukin 2-driven T-lymphocyte proliferation by prolactin. Proc. Natl. Acad. Sci. U. 
S. A 87, 6460-6464. 
Cline,A.M. and Radic,M.Z. (2004). Apoptosis, subcellular particles, and autoimmunity. 
Clin. Immunol. 112, 175-182. 
Coligan,J.E., Kruisbeek,A.M., Margulies,D.H., Shevach,E.M., and Strober,W. (1992). 
Measurement of proliferative responses of cultured lymphocytes. (New York: Wiley), p. 
7.10.1. 
Coqueret,O. (2002). Linking cyclins to transcriptional control. Gene 299, 35-55. 
Davies,S.P., Reddy,H., Caivano,M., and Cohen,P. (2000). Specificity and mechanism of 
action of some commonly used protein kinase inhibitors. Biochem. J. 351, 95-105. 
Despouy,G., Bastie,J.N., Deshaies,S., Balitrand,N., Mazharian,A., Rochette-Egly,C., 
Chomienne,C., and Delva,L. (2003). Cyclin D3 is a cofactor of retinoic acid receptors, 
modulating their activity in the presence of cellular retinoic acid-binding protein II. J. 
Biol. Chem. 278, 6355-6362. 
Diehn,M., Alizadeh,A.A., Rando,O.J., Liu,C.L., Stankunas,K., Botstein,D., 
Crabtree,G.R., and Brown,P.O. (2002). Genomic expression programs and the integration 
of the CD28 costimulatory signal in T cell activation. Proc. Natl. Acad. Sci. U. S. A 99, 
11796-11801. 
   92 
 
Dolbeare,F., Gratzner,H., Pallavicini,M.G., and Gray,J.W. (1983). Flow cytometric 
measurement of total DNA content and incorporated bromodeoxyuridine. Proc. Natl. 
Acad. Sci. U. S. A 80, 5573-5577. 
Dyson,N. (1998). The regulation of E2F by pRB-family proteins. Genes Dev. 12, 2245-
2262. 
Ekholm,S.V. and Reed,S.I. (2000). Regulation of G(1) cyclin-dependent kinases in the 
mammalian cell cycle. Curr. Opin. Cell Biol. 12, 676-684. 
Ellery,J.M. and Nicholls,P.J. (2002). Alternate signalling pathways from the interleukin-2 
receptor. Cytokine Growth Factor Rev. 13, 27-40. 
Endresen,P. and Aarbakke,J. (1992). [Apoptosis and cytostatic agents]. Tidsskr. Nor 
Laegeforen. 112, 1594-1596. 
Engedal,N., Ertesvag,A., and Blomhoff,H.K. (2004). Survival of activated human T 
lymphocytes is promoted by retinoic acid via induction of IL-2. Int. Immunol. 16, 443-
453. 
Ertesvag,A., Engedal,N., Naderi,S., and Blomhoff,H.K. (2002). Retinoic acid stimulates 
the cell cycle machinery in normal T cells: involvement of retinoic acid receptor-
mediated IL-2 secretion. J. Immunol. 169, 5555-5563. 
Escriva,H., Safi,R., Hanni,C., Langlois,M.C., Saumitou-Laprade,P., Stehelin,D., 
Capron,A., Pierce,R., and Laudet,V. (1997). Ligand binding was acquired during 
evolution of nuclear receptors. Proc. Natl. Acad. Sci. U. S. A 94, 6803-6808. 
Fahlman,C., Jacobsen,S.E., Smeland,E.B., Lomo,J., Naess,C.E., Funderud,S., and 
Blomhoff,H.K. (1995). All-trans- and 9-cis-retinoic acid inhibit growth of normal human 
and murine B cell precursors. J. Immunol. 155, 58-65. 
Firpo,E.J., Koff,A., Solomon,M.J., and Roberts,J.M. (1994). Inactivation of a Cdk2 
inhibitor during interleukin 2-induced proliferation of human T lymphocytes. Mol. Cell 
Biol. 14, 4889-4901. 
Fish,L.A., Baxter,C.S., and Bash,J.A. (1981). Murine lymphocyte comitogenesis by 
phorbol esters, and its inhibition by retinoic acid and inhibitors of polyamine 
biosynthesis. Toxicol. Appl. Pharmacol. 58, 39-47. 
Flores,I., Jones,D.R., Cipres,A., Diaz-Flores,E., Sanjuan,M.A., and Merida,I. (1999). 
Diacylglycerol kinase inhibition prevents IL-2-induced G1 to S transition through a 
phosphatidylinositol-3 kinase-independent mechanism. J. Immunol. 163, 708-714. 
Friedman,A., Halevy,O., Schrift,M., Arazi,Y., and Sklan,D. (1993). Retinoic acid 
promotes proliferation and induces expression of retinoic acid receptor-alpha gene in 
murine T lymphocytes. Cell Immunol. 152, 240-248. 
   93 
 
Fuchs,E. and Green,H. (1981). Regulation of terminal differentiation of cultured human 
keratinocytes by vitamin A. Cell 25, 617-625. 
Fung,T.K. and Poon,R.Y. (2005). A roller coaster ride with the mitotic cyclins. Semin. 
Cell Dev. Biol. 16, 335-342. 
Garbe,A., Buck,J., and Hammerling,U. (1992). Retinoids are important cofactors in T cell 
activation. J. Exp. Med. 176, 109-117. 
Garcia-Gras,E.A., Chi,P., and Thompson,E.A. (2000). Glucocorticoid-mediated 
destabilization of cyclin D3 mRNA involves RNA-protein interactions in the 3'-
untranslated region of the mRNA. J. Biol. Chem. 275, 22001-22008. 
Gesbert,F., Delespine-Carmagnat,M., and Bertoglio,J. (1998). Recent advances in the 
understanding of interleukin-2 signal transduction. J. Clin. Immunol. 18, 307-320. 
Green,D.R. (2005). Apoptotic pathways: ten minutes to dead. Cell 121, 671-674. 
Gronemeyer,H. and Miturski,R. (2001). Molecular mechanisms of retinoid action. Cell 
Mol. Biol. Lett. 6, 3-52. 
Guttridge,D.C., Albanese,C., Reuther,J.Y., Pestell,R.G., and Baldwin,A.S., Jr. (1999). 
NF-kappaB controls cell growth and differentiation through transcriptional regulation of 
cyclin D1. Mol. Cell Biol. 19, 5785-5799. 
Gutzkow,K.B., Lahne,H.U., Naderi,S., Torgersen,K.M., Skalhegg,B., Koketsu,M., 
Uehara,Y., and Blomhoff,H.K. (2003). Cyclic AMP inhibits translation of cyclin D3 in T 
lymphocytes at the level of elongation by inducing eEF2-phosphorylation. Cell Signal. 
15, 871-881. 
Harbour,J.W. and Dean,D.C. (2000a). Rb function in cell-cycle regulation and apoptosis. 
Nat. Cell Biol. 2, E65-E67. 
Harbour,J.W. and Dean,D.C. (2000b). The Rb/E2F pathway: expanding roles and 
emerging paradigms. Genes Dev. 14, 2393-2409. 
Hatakeyama,M., Brill,J.A., Fink,G.R., and Weinberg,R.A. (1994). Collaboration of G1 
cyclins in the functional inactivation of the retinoblastoma protein. Genes Dev. 8, 1759-
1771. 
Hildeman,D.A., Mitchell,T., Kappler,J., and Marrack,P. (2003). T cell apoptosis and 
reactive oxygen species. J. Clin. Invest 111, 575-581. 
Hildeman,D.A., Zhu,Y., Mitchell,T.C., Kappler,J., and Marrack,P. (2002). Molecular 
mechanisms of activated T cell death in vivo. Curr. Opin. Immunol. 14, 354-359. 
   94 
 
Hleb,M., Murphy,S., Wagner,E.F., Hanna,N.N., Sharma,N., Park,J., Li,X.C., Strom,T.B., 
Padbury,J.F., Tseng,Y.T., and Sharma,S. (2004). Evidence for cyclin D3 as a novel target 
of rapamycin in human T lymphocytes. J. Biol. Chem. 279, 31948-31955. 
Horowitz,J.M., Yandell,D.W., Park,S.H., Canning,S., Whyte,P., Buchkovich,K., 
Harlow,E., Weinberg,R.A., and Dryja,T.P. (1989). Point mutational inactivation of the 
retinoblastoma antioncogene. Science 243, 937-940. 
Hu,Q.J., Dyson,N., and Harlow,E. (1990). The regions of the retinoblastoma protein 
needed for binding to adenovirus E1A or SV40 large T antigen are common sites for 
mutations. EMBO J. 9, 1147-1155. 
Isakov,N. and Altman,A. (1987). Human T lymphocyte activation by tumor promoters: 
role of protein kinase C. J. Immunol. 138, 3100-3107. 
Ishida,S., Kinoshita,T., Sugawara,N., Yamashita,T., and Koike,K. (2003). Serum 
inhibitors for human mast cell growth: possible role of retinol. Allergy 58, 1044-1052. 
Jiang,X.L., Dillehay,D.L., Everson,M.P., Tilden,A.B., and Lamon,E.W. (1992). 
Potentiation of IL-2-induced t-cell proliferation by retinoids. Int. J. Immunopharmacol. 
14, 195-204. 
Jiang,X.L., Everson,M.P., and Lamon,E.W. (1993). A mechanism of retinoid potentiation 
of murine T-cell responses: early upregulation of interleukin-2 receptors. Int. J. 
Immunopharmacol. 15, 309-317. 
Kang,J.X., Bell,J., Beard,R.L., and Chandraratna,R.A. (1999). Mannose 6-
phosphate/insulin-like growth factor II receptor mediates the growth-inhibitory effects of 
retinoids. Cell Growth Differ. 10, 591-600. 
Keidel,S., LeMotte,P., and Apfel,C. (1994). Different agonist- and antagonist-induced 
conformational changes in retinoic acid receptors analyzed by protease mapping. Mol. 
Cell Biol. 14, 287-298. 
Kilpatrick,D.C. (1999). Mechanisms and assessment of lectin-mediated mitogenesis. 
Mol. Biotechnol. 11, 55-65. 
Kirken,R.A., Erwin,R.A., Taub,D., Murphy,W.J., Behbod,F., Wang,L., Pericle,F., and 
Farrar,W.L. (1999). Tyrphostin AG-490 inhibits cytokine-mediated JAK3/STAT5a/b 
signal transduction and cellular proliferation of antigen-activated human T cells. J. 
Leukoc. Biol. 65, 891-899. 
Kliewer,S.A., Umesono,K., Mangelsdorf,D.J., and Evans,R.M. (1992). Retinoid X 
receptor interacts with nuclear receptors in retinoic acid, thyroid hormone and vitamin D3 
signalling. Nature 355, 446-449. 
   95 
 
Knudsen,K.E., Fribourg,A.F., Strobeck,M.W., Blanchard,J.M., and Knudsen,E.S. (1999). 
Cyclin A is a functional target of retinoblastoma tumor suppressor protein-mediated cell 
cycle arrest. J. Biol. Chem. 274, 27632-27641. 
Konta,T., Xu,Q., Furusu,A., Nakayama,K., and Kitamura,M. (2001). Selective roles of 
retinoic acid receptor and retinoid x receptor in the suppression of apoptosis by all-trans-
retinoic acid. J. Biol. Chem. 276, 12697-12701. 
Kroemer,G. and Martin,S.J. (2005). Caspase-independent cell death. Nat. Med. 11, 725-
730. 
Kucharz,E.J. and Goodwin,J.S. (1988). Serum inhibitors of interleukin-2. Life Sci. 42, 
1485-1491. 
Kwon,T.K., Buchholz,M.A., Ponsalle,P., Chrest,F.J., and Nordin,A.A. (1997). The 
regulation of p27Kip1 expression following the polyclonal activation of murine G0 T 
cells. J. Immunol. 158, 5642-5648. 
LaBaer,J., Garrett,M.D., Stevenson,L.F., Slingerland,J.M., Sandhu,C., Chou,H.S., 
Fattaey,A., and Harlow,E. (1997). New functional activities for the p21 family of CDK 
inhibitors. Genes Dev. 11, 847-862. 
Lea,N.C., Orr,S.J., Stoeber,K., Williams,G.H., Lam,E.W., Ibrahim,M.A., Mufti,G.J., and 
Thomas,N.S. (2003). Commitment point during G0-->G1 that controls entry into the cell 
cycle. Mol. Cell Biol. 23, 2351-2361. 
Lea,T. (2000). Basal og klinisk immunologi -prinsipper og molekylære mekanismer. 
Fagbokforlaget Vigmostad & Bjørke AS). 
Leblanc,B.P. and Stunnenberg,H.G. (1995). 9-cis retinoic acid signaling: changing 
partners causes some excitement. Genes Dev. 9, 1811-1816. 
Lee,J.O., Russo,A.A., and Pavletich,N.P. (1998). Structure of the retinoblastoma tumour-
suppressor pocket domain bound to a peptide from HPV E7. Nature 391, 859-865. 
Lin,J.X. and Leonard,W.J. (1997). Signaling from the IL-2 receptor to the nucleus. 
Cytokine Growth Factor Rev. 8, 313-332. 
Lomo,J., Smeland,E.B., Ulven,S., Natarajan,V., Blomhoff,R., Gandhi,U., Dawson,M.I., 
and Blomhoff,H.K. (1998). RAR-, not RXR, ligands inhibit cell activation and prevent 
apoptosis in B-lymphocytes. J Cell Physiol 175, 68-77. 
Lukas,J., Herzinger,T., Hansen,K., Moroni,M.C., Resnitzky,D., Helin,K., Reed,S.I., and 
Bartek,J. (1997). Cyclin E-induced S phase without activation of the pRb/E2F pathway. 
Genes Dev. 11, 1479-1492. 
   96 
 
Mangelsdorf,D.J., Umesono,K., Kliewer,S.A., Borgmeyer,U., Ong,E.S., and Evans,R.M. 
(1991). A direct repeat in the cellular retinol-binding protein type II gene confers 
differential regulation by RXR and RAR. Cell 66, 555-561. 
Maniatis,T., Fritch,E.F., and Sambrock,J. (1989). Molecular cloning. (New York: Cold 
Spring Harbor). 
Martelli,A.M., Zweyer,M., Ochs,R.L., Tazzari,P.L., Tabellini,G., Narducci,P., and 
Bortul,R. (2001). Nuclear apoptotic changes: an overview. J. Cell Biochem. 82, 634-646. 
Mastro,A.M. and Pepin,K.G. (1982). The effects of retinoic acid and a tumor promoter, 
12-O-tetradecanoylphorbol-13-acetate, on lymphocyte proliferation. Carcinogenesis 3, 
409-413. 
McGowan,C.H. (2003). Regulation of the eukaryotic cell cycle. Prog. Cell Cycle Res. 5, 
1-4. 
Modiano,J.F., Domenico,J., Szepesi,A., Terada,N., Lucas,J.J., and Gelfand,E.W. (1995). 
Symmetry of the activation of cyclin-dependent kinases in mitogen and growth factor-
stimulated T lymphocytes. Ann. N. Y. Acad. Sci. 766, 134-148. 
Mohapatra,S., Agrawal,D., and Pledger,W.J. (2001). p27Kip1 regulates T cell 
proliferation. J. Biol. Chem. 276, 21976-21983. 
Moon,J.J. and Nelson,B.H. (2001). Phosphatidylinositol 3-kinase potentiates, but does 
not trigger, T cell proliferation mediated by the IL-2 receptor. J. Immunol. 167, 2714-
2723. 
Morgan,D.O. (1997). Cyclin-dependent kinases: engines, clocks, and microprocessors. 
Annu. Rev. Cell Dev. Biol. 13, 261-291. 
Muise-Helmericks,R.C., Grimes,H.L., Bellacosa,A., Malstrom,S.E., Tsichlis,P.N., and 
Rosen,N. (1998). Cyclin D expression is controlled post-transcriptionally via a 
phosphatidylinositol 3-kinase/Akt-dependent pathway. J. Biol. Chem. 273, 29864-29872. 
Muller,H. and Helin,K. (2000). The E2F transcription factors: key regulators of cell 
proliferation. Biochim. Biophys. Acta 1470, M1-12. 
Mustelin,T. and Tasken,K. (2003). Positive and negative regulation of T-cell activation 
through kinases and phosphatases. Biochem. J. 371, 15-27. 
Naderi,S. and Blomhoff,H.K. (1999). Retinoic acid prevents phosphorylation of pRB in 
normal human B lymphocytes: regulation of cyclin E, cyclin A, and p21(Cip1). Blood 94, 
1348-1358. 
Naderi,S., Gutzkow,K.B., Lahne,H.U., Lefdal,S., Ryves,W.J., Harwood,A.J., and 
Blomhoff,H.K. (2004). cAMP-induced degradation of cyclin D3 through association with 
GSK-3beta. J. Cell Sci. 117, 3769-3783. 
   97 
 
Nauss,K.M. (1986). Influence of Vitamin A Status on the Immune System. In Vitamin A 
Deficiency and its Control, (San Diego, CA: Academic Press,Inc.), p. 207. 
Nelson,B.H. and Willerford,D.M. (1998). Biology of the interleukin-2 receptor. Adv. 
Immunol. 70, 1-81. 
Nishizuka,Y. (1984). The role of protein kinase C in cell surface signal transduction and 
tumour promotion. Nature 308, 693-698. 
Nourse,J., Firpo,E., Flanagan,W.M., Coats,S., Polyak,K., Lee,M.H., Massague,J., 
Crabtree,G.R., and Roberts,J.M. (1994). Interleukin-2-mediated elimination of the 
p27Kip1 cyclin-dependent kinase inhibitor prevented by rapamycin. Nature 372, 570-
573. 
Olashaw,N., Bagui,T.K., and Pledger,W.J. (2004). Cell cycle control: a complex issue. 
Cell Cycle 3, 263-264. 
Pallet,N., Thervet,E., Le Corre,D., Knebelmann,B., Nusbaum,P., Tomkiewicz,C., 
Meria,P., Flinois,J.P., Beaune,P., Legendre,C., and Anglicheau,D. (2005). Rapamycin 
inhibits human renal epithelial cell proliferation: effect on cyclin D3 mRNA expression 
and stability. Kidney Int. 67, 2422-2433. 
Perez-Roger,I., Kim,S.H., Griffiths,B., Sewing,A., and Land,H. (1999). Cyclins D1 and 
D2 mediate myc-induced proliferation via sequestration of p27(Kip1) and p21(Cip1). 
EMBO J. 18, 5310-5320. 
Peters,J.M. (1998). SCF and APC: the Yin and Yang of cell cycle regulated proteolysis. 
Curr. Opin. Cell Biol. 10, 759-768. 
Pines,J. (1995). Cyclins, CDKs and cancer. Semin. Cancer Biol. 6, 63-72. 
Pines,J. (1999). Four-dimensional control of the cell cycle. Nat. Cell Biol. 1, E73-E79. 
Planas-Silva,M.D. and Weinberg,R.A. (1997). The restriction point and control of cell 
proliferation. Curr. Opin. Cell Biol. 9, 768-772. 
Radominska-Pandya,A., Chen,G., Czernik,P.J., Little,J.M., Samokyszyn,V.M., 
Carter,C.A., and Nowak,G. (2000). Direct interaction of all-trans-retinoic acid with 
protein kinase C (PKC). Implications for PKC signaling and cancer therapy. J. Biol. 
Chem. 275, 22324-22330. 
Rameh,L.E., Arvidsson,A., Carraway,K.L., III, Couvillon,A.D., Rathbun,G., 
Crompton,A., VanRenterghem,B., Czech,M.P., Ravichandran,K.S., Burakoff,S.J., 
Wang,D.S., Chen,C.S., and Cantley,L.C. (1997). A comparative analysis of the 
phosphoinositide binding specificity of pleckstrin homology domains. J. Biol. Chem. 
272, 22059-22066. 
   98 
 
Rameh,L.E. and Cantley,L.C. (1999). The role of phosphoinositide 3-kinase lipid 
products in cell function. J. Biol. Chem. 274, 8347-8350. 
Resnitzky,D. and Reed,S.I. (1995). Different roles for cyclins D1 and E in regulation of 
the G1-to-S transition. Mol. Cell Biol. 15, 3463-3469. 
Rodel,F., Franz,S., Sheriff,A., Gaipl,U., Heyder,P., Hildebrandt,G., Schultze-Mosgau,S., 
Voll,R.E., and Herrmann,M. (2005). The CFSE distribution assay is a powerful technique 
for the analysis of radiation-induced cell death and survival on a single-cell level. 
Strahlenther. Onkol. 181, 456-462. 
Ross,A.C. (1992). Vitamin A status: relationship to immunity and the antibody response. 
Proc. Soc. Exp. Biol. Med. 200, 303-320. 
Ross,A.C. and Stephensen,C.B. (1996). Vitamin A and retinoids in antiviral responses. 
FASEB J. 10, 979-985. 
Roy,B., Taneja,R., and Chambon,P. (1995). Synergistic activation of retinoic acid (RA)-
responsive genes and induction of embryonal carcinoma cell differentiation by an RA 
receptor alpha (RAR alpha)-, RAR beta-, or RAR gamma-selective ligand in combination 
with a retinoid X receptor-specific ligand. Mol. Cell Biol. 15, 6481-6487. 
Russell,P. and Nurse,P. (1987). Negative regulation of mitosis by wee1+, a gene 
encoding a protein kinase homolog. Cell 49, 559-567. 
Salmon,M., Pilling,D., Borthwick,N.J., Viner,G., Janossy,G., Bacon,P.A., and 
Akbar,A.N. (1994). The progressive differentiation of primed T cells is associated with 
an increasing susceptibility to apoptosis. Eur. J. Immunol. 24:892. 
Sanjuan,M.A., Pradet-Balade,B., Jones,D.R., Martinez,A., Stone,J.C., Garcia-Sanz,J.A., 
and Merida,I. (2003). T cell activation in vivo targets diacylglycerol kinase alpha to the 
membrane: a novel mechanism for Ras attenuation. J. Immunol. 170, 2877-2883. 
Santoni-Rugiu,E., Falck,J., Mailand,N., Bartek,J., and Lukas,J. (2000). Involvement of 
Myc activity in a G(1)/S-promoting mechanism parallel to the pRb/E2F pathway. Mol. 
Cell Biol. 20, 3497-3509. 
Schrum,A.G., Turka,L.A., and Palmer,E. (2003). Surface T-cell antigen receptor 
expression and availability for long-term antigenic signaling. Immunol. Rev. 196, 7-24. 
Schulze,A., Zerfass-Thome,K., Berges,J., Middendorp,S., Jansen-Durr,P., and 
Henglein,B. (1996). Anchorage-dependent transcription of the cyclin A gene. Mol. Cell 
Biol. 16, 4632-4638. 
Sears,R.C. and Nevins,J.R. (2002). Signaling networks that link cell proliferation and cell 
fate. J. Biol. Chem. 277, 11617-11620. 
   99 
 
Semba,R.D. (1999). Vitamin A and immunity to viral, bacterial and protozoan infections. 
Proc. Nutr. Soc. 58, 719-727. 
Semba,R.D., Ndugwa,C., Perry,R.T., Clark,T.D., Jackson,J.B., Melikian,G., Tielsch,J., 
and Mmiro,F. (2005). Effect of periodic vitamin A supplementation on mortality and 
morbidity of human immunodeficiency virus-infected children in Uganda: A controlled 
clinical trial. Nutrition 21, 25-31. 
Sherr,C.J. (1996). Cancer cell cycles. Science 274, 1672-1677. 
Sherr,C.J. and Roberts,J.M. (1999). CDK inhibitors: positive and negative regulators of 
G1-phase progression. Genes Dev. 13, 1501-1512. 
Sidell,N., Chang,B., and Bhatti,L. (1993). Upregulation by retinoic acid of interleukin-2-
receptor mRNA in human T lymphocytes. Cell Immunol. 146, 28-37. 
Sidell,N., Kummer,U., Aframian,D., and Thierfelder,S. (1997). Retinoid regulation of 
interleukin-2 receptors on human T-cells. Cell Immunol. 179, 116-125. 
Sidell,N. and Ramsdell,F. (1988). Retinoic acid upregulates interleukin-2 receptors on 
activated human thymocytes. Cell Immunol. 115, 299-309. 
Sommer,A. (1993a). Vitamin A supplementation and childhood morbidity. Lancet 342, 
1420. 
Sommer,A. (1993b). Vitamin A, infectious disease, and childhood mortality: a 2 
solution? J. Infect. Dis. 167, 1003-1007. 
Sonenberg,N. and Gingras,A.C. (1998). The mRNA 5' cap-binding protein eIF4E and 
control of cell growth. Curr. Opin. Cell Biol. 10, 268-275. 
Stephensen,C.B. (2001). Vitamin A, infection, and immune function. Annu. Rev. Nutr. 
21, 167-192. 
Swat,W., Ignatowicz,L., and Kisielow,P. (1991). Detection of apoptosis of immature 
CD4+8+ thymocytes by flow cytometry. J. Immunol. Methods 137, 79-87. 
Takahashi,N. and Breitman,T.R. (1994). Retinolylation of Proteins in Mammalian Cells. 
In Vitamin A in Health and Disease, B.Rune, ed., pp. 257-273. 
Valone,F.H. and Payan,D.G. (1985). Potentiation of mitogen-induced human T-
lymphocyte activation by retinoic acid. Cancer Res. 45, 4128-4131. 
Villamor,E. and Fawzi,W.W. (2005). Effects of vitamin a supplementation on immune 
responses and correlation with clinical outcomes. Clin. Microbiol. Rev. 18, 446-464. 
Walker,N.I., Harmon,B.V., Gobe,G.C., and Kerr,J.F. (1988). Patterns of cell death. 
Methods Achiev. Exp. Pathol. 13, 18-54. 
   100 
 
Wang,L.H., Kirken,R.A., Erwin,R.A., Yu,C.R., and Farrar,W.L. (1999). JAK3, STAT, 
and MAPK signaling pathways as novel molecular targets for the tyrphostin AG-490 
regulation of IL-2-mediated T cell response. J. Immunol. 162, 3897-3904. 
Wen,Z., Zhong,Z., and Darnell,J.E., Jr. (1995). Maximal activation of transcription by 
Stat1 and Stat3 requires both tyrosine and serine phosphorylation. Cell 82, 241-250. 
Yam,C.H., Fung,T.K., and Poon,R.Y. (2002). Cyclin A in cell cycle control and cancer. 
Cell Mol. Life Sci. 59, 1317-1326. 
Yu,Q., Ciemerych,M.A., and Sicinski,P. (2005). Ras and Myc can drive oncogenic cell 
proliferation through individual D-cyclins. Oncogene 24, 7114-7119. 
Zetterberg,A., Larsson,O., and Wiman,K.G. (1995). What is the restriction point? Curr. 
Opin. Cell Biol. 7, 835-842. 
Zhang,W., Bergamaschi,D., Jin,B., and Lu,X. (2005). Posttranslational modifications of 
p27kip1 determine its binding specificity to different cyclins and cyclin-dependent 
kinases in vivo. Blood 105, 3691-3698. 
 
